




Defining interactions between assembling HIV-1  
virions and host cell plasma membrane proteins 
By 
Jonathan Richard Grover 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of  
Doctor of Philosophy 
(Microbiology and Immunology) 







Associate Professor Akira Ono, Chair 
Professor Kathleen L. Collins 
Professor Alice Telesnitsky 
































 I would like to graciously thank the many who have encouraged and guided me 
along the path to reach this point in my career. Specifically, I would like to thank K.R. 
Scott, Jeff Hengesbach, and Mr. Faust from Mountain Pointe High School; James Birk, 
Shelley Haydel, Yixin Shi, Valerie Stout, Hugh Mason, Barbara Gonzales, Jacquelyn 
Kilbourne, Deirdre Meldrum, Mark Holl, Roger Johnson, and Jeff Houkal from Arizona 
State University.  
I would like to thank my thesis committee members Alice Telesnitsky and Kathy 
Collins for their many insightful suggestions and support at every stage of my graduate 
career. In particular, I would like to thank Akira Ono for his inexhaustible patience and 
optimism, he truly has been an outstanding friend, example, and mentor to me over the 
past 5 years. I would also like to acknowledge Sarah Veatch, who has served on my 
thesis committee, as well as collaborating with me on several projects. Sarah has been a 
friend, colleague and second mentor to me and I have greatly benefitted from her 
unwavering dedication to rigorous interpretation of experimental data. I would like to 
thank Christiane Wobus and Joel Swanson for allowing me to rotate in their labs. I would 
also like to thank the many faculty members who have provided advice, encouragement, 
suggestions, and reagents to me over the years, including Mike Imperiale, Phil Hanna 
(MIC405), Elliot Juni (MIC350), Vic DiRita (MMMP), Harry Mobley, Kathy Spindler 
(MIC415), Phil King, Steve King (BSL-3), Malini Raghavan, Cheong-Hee Chang, Beth 
Moore (MIC415), Tom Moore (MIC460), Jason Weinberg (Virology Journal Club), Bob 
Fuller (Intracellular Protein Trafficking Club), and Aaron Goldstrohm, as well as many 
others not listed here. 
iv 
 
I would like to thank past and present members of the Ono Lab for their 
friendship, help, and guidance, including Ian Hogue, Vineela Chukkapalli, Nick 
Llewellyn, Kazuaki Monde, Jingga Inlora, Balaji Olety Amaranath, Gabrielle Todd, Jenni 
Chung, Madeline Nye, Jay Oh, Alex Myong, and Ed Trubin. I would like to thank the 
Veatch laboratory, especially Matt Stone, Elin Edwald, Jiang Zhao and Jing Wu for their 
help with my experiments and data analysis. I would like to thank the staff of the 
Department of Microbiology and Immunology, especially Heidi Thompson and Margaret 
Allen. I would also like to thank Sam Straight from the Center for Live-Cell Imaging and 
Chris Edwards from the Microscopy and Image Analysis Laboratory. I would like to 
thank Seth Thacker and Keith Bishop for helping to recruit me to the University of 
Michigan, and Rob Peters for being an outstanding graduate student mentor. 
I would like to thank my parents Richard and Mary Grover for their love and for 
fostering my curiosity since childhood. They have always encouraged me to follow my 
passion for science wherever it takes me. I would like to thank my parents-in-law Heidi 
and Steve Robbins for their love and support. Finally, I would like to thank my loving, 
beautiful wife Natasha for her constant support and patience with me, even when I stay 
on the microscope all night, and my son Garrett for giving me a good excuse not to work 
every single night and weekend over the past two years. 
I would like to acknowledge the organizations and institutions which have 
generously provided funding to support my graduate school career. I received one year of 
funding from the Program in Biomedical Sciences (PiBS) at the University of Michigan. I 
received two years of funding from the Molecular Mechanisms in Microbial Pathogenesis 
Training Program (MMMP, T32 AI007527-13), administered by Professor Victor DiRita. 
v 
 
I also received one year of funding from the Doctor Clayton Willison and Emma 
Elizabeth Willison Fund, administered by the Department of Microbiology and 
Immunology. The work presented in this thesis was further supported by the National 
Institutes of Health (R56 AI089282 and R21 AI095022). 
The work presented in Chapter 2 of this thesis has been published previously: 
 
Grover JR, Llewellyn GN, Soheilian F, Nagashima K, Veatch S, Ono A. (2013) Roles 
Played by Capsid-Dependent Induction of Membrane Curvature and Gag-ESCRT 
Interactions in Tetherin Recruitment to HIV-1 Assembly Sites. Journal of Virology 
87(8):4650-4664. 
 
Transmission electron microscopy analysis of Gag mutants, presented in Figure 
2.3A, was performed by Ferri Soheilian and Kunio Nagashima at the Electron 
Microscopy Laboratory, SAIC-Frederick, Inc., National Cancer Institute, Frederick, MD. 
T cell infection and microscopy, presented in Figure 2.4 was performed with the 
assistance of G. Nicholas Llewellyn. Super-resolution localization microscopy 
experiments and data analyses, presented in Figures 2.5, 2.7, 3.1, 3.2, 3.3, 3.4, and 4.2, 
were performed in collaboration with Sarah Veatch in the Department of Biophysics at 






























Overview of the HIV pandemic and HIV pathogenesis……….….1 
   
  The HIV Replication Cycle……………………………………….3 
 
  Restriction Factors and Viral Countermeasures…………………11 
 
  Super-Resolution Microscopy Techniques and Applications……17 
 
  References………………………………………………………..23 
 
 
II. Roles played by capsid-dependent induction of membrane curvature 





  Introduction………………………………………………………37 
 
  Materials and Methods…………………………………………...39 
 
  Results……………………………………………………………47 
 
  Discussion………………………………………………………..66 
 
  Acknowledgements………………………………………………71 
 





III. Characterization of HIV-1 interactions with uropod-directed 















































List of Figures 
 
Figure 1.1. Schematic representation of the HIV-1 genome…………………………..4 
 
Figure 1.2. Overview of the HIV-1 life cycle…………………………………………...5 
 
Figure 1.3. Schematic representation of a polarized T cell…………….…...…………7 
 
Figure 1.4. Explanation of total internal reflection microscopy (TIRF)…...………..20 
 
Figure 1.5. Schematic overview of dSTORM and PALM techniques used  
in this thesis……………………………………………………………………………..21 
 
Figure 2.1. Tetherin copatches with Gag-YFP but not with CD46 or  
lipid raft markers…………….………………………………………………………....48 
 
Figure 2.2. Tetherin antiviral function is insensitive to cholesterol depletion...…....50 
 
Figure 2.3. Membrane curvature and Tsg101 binding correlate with  
tetherin recruitment in HeLa cells…………………………………………………….52 
 
Figure 2.4. Both Tsg101- and Alix-binding sites in Gag are required for  
maximal tetherin recruitment in T cells………………………………………………56 
 
Figure 2.5. siRNA-mediated depletion of Tsg101 or Alix decreases  
tetherin recruitment in HeLa cells…………………………………………………….58 
 
Figure 2.6. Disruption of Gag-ESCRT interactions does not affect  
tetherin function….……………………………………………………………………..61 
 
Figure 2.7. Both membrane curvature and Gag-ESCRT interactions enhance  
tetherin recruitment in HeLa cells…………………………………………………….64 
 
Figure 3.1. The basic charge of MA HBR promotes co-clustering of Gag and  
PSGL-1 in HeLa cells………………………………….………………………………..89 
 
Figure 3.2. The cytoplasmic tail of PSGL-1, not dimerization, is required for  
co-clustering with Gag……………………………………………………………...…..91 
 
Figure 3.3. Basic residues in the cytoplasmic tail of PSGL-1 enhance co-clustering  
with Gag…………………………………………………………………………………93 
 
Figure 3.4. ERM proteins decrease co-clustering of Gag and PSGL-1…..………..95 
 
Figure 3.5. PSGL-1, CD43, CD44, and ICAM-3 decrease infectivity and cell-to-cell 
transfer of HIV-1……………………………………………………………………….99 
ix 
 
Figure 4.1. Development of a trans-infection assay using THP-1-derived, human 
dendritic cells...…………………………………………………………………….…..121 
 






































Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired 
immunodeficiency syndrome (AIDS) and is a significant burden on human health. As a 
successful pathogen, HIV-1 is able to overcome several components of the innate and 
adaptive immune systems. This is facilitated by the activities of the four accessory 
proteins Vif, Vpr, Vpu, and Nef.  
The Vpu protein has been shown to target an antiviral protein, BST-2/tetherin, 
which inhibits the release of many enveloped viruses from infected cells. While much is 
known about the mechanism of tetherin antagonism by Vpu, the antiviral function of 
tetherin is poorly understood. It has been observed that tetherin is specifically recruited to 
sites of HIV-1 assembly, but the mechanism of this recruitment is unknown. 
In my thesis work I have employed conventional and super-resolution microscopy 
techniques to determine the mechanism of tetherin recruitment to HIV-1 assembly sites. I 
have determined that both membrane curvature, mediated by the HIV-1 Gag protein, as 
well as interactions between Gag and the ESCRT machinery are the critical determinants 
of tetherin recruitment to HIV-1 assembly sites. I have also demonstrated that low levels 
of tetherin recruitment, induced by membrane curvature, are sufficient for inhibition of 
HIV-1 release. 
Currently I am employing super-resolution microscopy to study interactions 
between HIV and other host proteins. Previously, we have shown that HIV interacts with 
and reorganizes plasma membrane microdomains in infected cells. In polarized T cells, 
which are a natural host of HIV-1 infection in vivo, we have shown that multimerization 
of Gag mediates polarization of HIV-1 particles to a rear-end protrusion termed the 
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uropod. Several proteins co-polarize with Gag to uropods, in a manner dependent upon 
the matrix domain of Gag.  
My current work involves characterization of interactions between HIV-1 and 
PSGL-1, a protein which is specifically recruited to virus assembly sites in T cells. I have 
found that basic residues within the cytoplasmic tail of this protein are required for its 
recruitment to HIV-1 assembly sites. I am also employing conventional assays to 
examine the affects of various uropod-directed proteins, such as PSGL-1, on HIV-1 








Overview of the HIV pandemic and HIV pathogenesis 
 Since its discovery in the early 1980s, HIV has spread world-wide, and remains a 
pandemic disease of great medical importance today [1-3]. There are currently 
approximately 34 million people living with HIV, with 2.5 million new infections and 1.7 
million HIV-related deaths in 2011[4]. Despite considerable effort, an effective vaccine 
remains elusive. However, significant progress has been made in combating HIV 
infection, transmission, and disease progression by the development of highly active 
antiretroviral therapy (HAART). In combination, these antiviral drugs can significantly 
improve outcomes for those already infected with HIV [5]. Expanding and improving 
upon existing HAART therapy, as well as making these medications inexpensive and 
universally available to HIV infected people world-wide remains an ongoing effort. Both 
of these goals must likely be met in order to bring the HIV pandemic to an end, and 
potentially drive HIV to extinction, as has been done with other viruses in the past [6].  
The establishment of a full-length, infectious molecular clone of HIV-1, soon 
after its discovery, has aided greatly in the study of HIV-1 molecular biology [7]. 
Understanding the molecular details of HIV replication, immune evasion, and virus-host 
interactions is a promising area for the identification of new drug targets, as well as the 
development of other strategies to combat HIV transmission and disease progression.  
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 HIV-1 is the causative agent of acquired immunodeficiency syndrome (AIDS) [1, 
2]. Following infection, viral titers rise and result in a temporary state of viremia. Once 
adaptive immune responses have been initiated, viral replication is significantly 
suppressed and viral titers decline to a low level, termed the set point. Importantly, 
however, the human immune system is unable to completely clear the infection and the 
patient enters a prolonged period of clinical latency. This period can last many years, 
especially when the patient is adherent to a regime of HAART therapy. Importantly, there 
is continued viral replication at low levels and adaptation of viral quasispecies which 
enhance viral fitness and provide the potential for the development of drug-resistance. 
The establishment of latent viral reservoirs within long-lived cell populations such as 
memory T cells and hematopoetic stem cells likely contribute to the inability of the 
immune system to completely clear HIV infection [8]. 
 Eventually, viral titers rise accompanied by a decline in CD4
+
 T cell counts, 
which are lysed by active HIV replication [1]. Once CD4
+
 T cell numbers fall below 200 
cells/ml of blood, the patient is considered to have clinical AIDS disease. At this point 
patients are particularly vulnerable to certain cancers, as well as a host of viral, bacterial, 
fungal, and parasitic infections, many of which are rarely seen in healthy individuals. 
Mortality of AIDS patients is always associated with one or more of these opportunistic 
infections rather than HIV itself [9]. Disease progression is also accelerated by the overall 
immune dysfunction, termed the bystander effect, which results from destruction of 
uninfected CD4
+
 T helper cells, which coordinate and direct adaptive immune responses 
[10, 11]. Identification and characterization of latent viral reservoirs and their elimination 
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by either pharmacologic agents, or their reactivation and subsequent elimination by the 
immune system remains a promising area of investigation [12, 13]. 
 
The HIV Replication Cycle 
 HIV-1 is an enveloped virus belonging to the retrovirus family and lentivirus 
genus (Group VI in the Baltimore classification system). It contains a linear, positive 
sense, RNA genome which encodes 9 viral proteins (15 after proteolytic cleavage events) 
(Figure 1.1). HIV-1 infection of cells begins with the binding of infectious virions to their 
primary receptor CD4 [14], found on the surface of a subset of T lymphocytes as well as 
cells of the myeloid lineage, such as macrophages and dendritic cells. This binding is 
mediated by trimeric complexes of the viral envelope glycoprotein (Env), which is 
composed of two subunits, gp120 and gp41. Following this initial binding event, Env is 
able to interact with one of two chemokine receptors, either CXCR4 or CCR5, depending 
upon the tropism of the viral Env protein as well as the type of cell being infected [15]. 
Once primary and secondary receptors have been engaged by Env, there is a dramatic 
conformational change which exposes the fusion peptide of gp41, which mediates the 
fusion of the viral envelope and cellular membrane [16] (Figure 1.2). 
 Once the viral capsid has entered the cell, it undergoes uncoating to release the 
pre-integration complex (PIC) into the host cell cytoplasm. This complex is composed of 
a dimer of single-stranded, positive-sense genomic RNA of approximately 10 kb in 
length (bearing a 5’ cap and 3’ poly-A tail similar to cellular mRNA molecules) as well 
as the viral reverse-transcriptase enzyme (RT) and the viral integrase enzyme (IN). This 
complex also contains the viral capsid (CA) and nucleocapsid proteins (NC), as well as 
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other cellular and viral proteins. Through the process of reverse-transcription, mediated 
by the RT enzyme, the viral RNA genome is converted into negative-sense DNA, using a 
specific host tRNA (tRNA
Lys3
) as a primer for DNA extension [17]. This is followed by 
synthesis of positive-sense DNA, also mediated by the RT enzyme, to yield a 
complementary double-stranded DNA molecule (cDNA) encoding the complete viral 
genome [18]. Upon interaction with the nuclear pore complex, the PIC is able to enter the 
nucleus, where viral cDNA is integrated into the host cell genome by the viral integrase 
enzyme [19, 20]. At this point the integrated provirus is able to function in a similar way 
to a host gene, which can be transcribed by the host RNA polymerase II, to give rise to 
both unspliced viral genomic RNA, as well as several spliced RNA species responsible 






Figure 1.1. Schematic representation of the HIV-1 genome.  
The HIV-1 genome is depicted as an integrated provirus composed of dsDNA which through LTR-
mediated transcription and differential splicing results in translation of all 9 viral proteins. The locations of 
coding regions of individual domains are shown for Gag, Pol, and Env proteins. The locations of important 
structural elements formed on viral RNA molecules are also indicated (TAR, , and RRE). LTR long 
terminal repeat, TAR trans-activation response element,  packaging signal, gag group specific antigen, 
MA matrix, CA capsid, NC nucleocapsid, p6 late domain, pol polymerase, PR protease, RT reverse 
transcriptase, IN integrase, vif viral infectivity factor, vpr viral protein R, vpu viral protein U, rev regulator 
of viral expression, tat trans-activator of transcription, env envelope, gp120 glycoprotein of 120 kDa, gp41 
glycoprotein of 41 kDa, nef negative factor. 
 
 Once the integrated provirus is actively transcribed, viral proteins can be 
expressed in the cytosol. Production of the trans-activator of transcription protein (Tat) 
greatly enhances the processivity and rate of viral gene transcription through its 
5 
 
interaction with a structural feature near the 5’ end of viral RNAs termed the trans-
activation response element (TAR) and host transcription factors [22-28]. Because 
eukaryotic mRNAs are normally sequestered within the nucleus until they have 
undergone splicing, the full-length viral RNA, which also serves as mRNA for translation 
of the Gag and GagPol proteins, cannot be efficiently translocated to the cytoplasm 
without the aid of the regulator of viral expression protein (Rev). This activity of Rev to 
facilitate nuclear export of unspliced, viral RNA is dependent upon its interaction with 
another structural feature of viral RNA, termed the rev-response element (RRE) [29-32] 





Figure 1.2. Overview of the HIV-1 life cycle.  
Major events in the replication cycle of HIV-1 are depicted along with known antiviral restriction factors 
and viral countermeasures. Life cycle events are labeled in plain black text. Restriction factors are shown in 
blue boxes linked to steps in the life cycle with which they interfere or inhibit. Viral countermeasures and 
accessory proteins are shown in red boxes. All accessory proteins depicted are from HIV-1, with the 
exception of HIV-2/SIV Vpx protein. The viral proteins Tat, Rev, Gag, GagPol, and Env are shown at 





 Upon translocation of full-length viral RNA into the cytoplasm, the viral 
precursor poly-proteins Gag and GagPol can be produced. The Gag protein is necessary 
and sufficient for the coordinated assembly of virus particles at the plasma membrane 
[33].  The GagPol fusion protein is synthesized through the aid of ribosomal 
frameshifting at a poly-purine tract located in the Sp2 region of the Gag coding sequence 
[34]. GagPol contains the viral enzymes protease (PR), reverse transcriptase (RT), and 
integrase (IN) fused, in tandem, to the C-terminus of the Gag precursor poly-protein [35] 
(Figures 1.1 and 1.2). 
 The Gag poly-protein is composed of 4 major structural domains, Matrix (MA), 
Capsid (CA), Nucleocapsid (NC), and the viral late domain (p6) (Figure 1.1). Removal of 
the initiator methionine residue of Gag, followed by N-terminal myristoylation of the 
exposed glycine residue by cellular enzymes allows Gag to stably interact with host cell 
membranes [36]. However, Gag also possesses the ability to interact specifically with 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] through the highly-basic region 
(HBR) of the MA domain. This interaction is thought to facilitate both binding and 
targeting of Gag to the plasma membrane, in which PI(4,5)P2 is predominantly found 
[37-41]. Once membrane binding has taken place, Gag has also been shown to interact 
with cholesterol-rich regions of the plasma membrane, termed lipid rafts [42]. Gag also 
interacts with other membrane microdomains such as tetraspanin-enriched microdomains 
(TEMs) [43-47] and uropod-directed microdomains (UDMs) in polarized T cells [48, 49] 
(Figure 1.3). In addition to interacting with membrane microdomains, Gag is also able to 





Figure 1.3. Schematic representation of a polarized T cell 
A migrating, polarized T cell is depicted adhered to a substrate. Cells migrate toward the leading edge, 
which is enriched in LFA-1. Uropod directed microdomains polarize toward the uropod, which is opposite 
the leading edge, and is near the MTOC. Gag preferentially associates with class I UDMs composed of 
PSGL-1, CD43, and CD44. Both class I and class II UDMs likely polarize through the participation of 
ERM proteins, which link transmembrane proteins to the cortical Actin cytoskeleton when activated. LFA-
1 lymphocyte adhesion glycoprotein 1, ERM Ezrin Radixin Moesin, ICAM-1 intracellular adhesion 
molecule 1, CD59 membrane attack complex inhibition factor, ICAM-3 intracellular adhesion molecule 3, 
PSGL-1 P-selectin glycoprotein ligand 1, CD43 Leukosialin, CD44 Extracellular matrix receptor III, 
MTOC Microtubule organizing center. 
 
 A previous study from our lab has demonstrated that assembling HIV-1 virions 
polarize to a rear end protrustion found in polarized T cells, termed the uropod. This 
polarization was found to be dependent upon membrane binding and higher-order 
multimerization of Gag, as well as a functional actin-myosin system. It was also shown 
that the presence of Gag in the uropod was correlated with increased cell-cell 
transmission of virus [48]. In unpolarized T cells, Gag has also been shown to interact 
with a subset of uropod-directed proteins (which normally polarize to uropods in the 
absence of Gag), termed class I uropod-directed microdomain (UDM) proteins, such as 
P-selectin glycoprotein ligand 1 (PSGL-1), Leukosialin (CD43), and Extracellular matrix 
receptor III (CD44). These interactions are dependent upon the overall charge, but not 
specific sequence of basic residues within the HBR of the MA domain. Interestingly, 
however, Gag does not associate with other UDM proteins such as Intracellular adhesion 
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molecules I and III (ICAM-1 and ICAM-3) or CD59, termed class II UDM proteins [49] 
(Figure 1.3).  
Although polarization of Gag to uropods does not appear to require interaction 
with specific class I UDM proteins, they do associate specifically and tightly with 
assembling HIV-1 virions [49]. Although it is likely that Gag may associate with certain 
UDM proteins and not others for some purpose, relevant in the context of in-vivo virus 
infection, the role of these proteins in viral replication and dissemination remains unclear. 
In chapter 3 of this thesis I will address the fundamental underlying mechanism which 
facilitates Gag-UDM interactions, as well as the potential modulation of different aspects 
of HIV-1 infection by these proteins. 
 Formation of viral particles is accomplished by the coordinated process of 
membrane binding and multimerization of Gag. Multimerization is primarily dependent 
upon residues in the C-terminal domain of capsid (CA-CTD), as well as basic residues in 
the NC domain, which bind to RNA which is thought to serve as a scaffold for viral 
assembly [52, 53]. It should be noted that there are additional residues within the N-
terminal domain of capsid (CA-NTD) which may also contribute to multimerization of 
Gag [54]. During the process of multimerization, Gag is able to produce positive 
membrane curvature in a processed termed virus budding [35]. This is likely mediated by 
residues in the CA-NTD, as well as a proposed structural change near the end of the CA-
CTD [55]. Before being packaged into virions, HIV genomic RNA forms dimers through 
base-pairing interactions at the dimerization initiation site (DIS) [56]. Through a highly 
regulated process, dimeric viral genomic RNA is then incorporated  into virus particles 
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by two zinc-finger motifs within the NC domain which interact with a structural motif of 
the viral RNA termed the packaging signal, or  element [57-59] (Figures 1.1 and 1.2). 
 The viral envelope glycoprotein (Env) is synthesized as a precursor protein 
(gp160), which is extensively glycosylated by host machinery in the endoplasmic 
reticulum and golgi apparatus. Following these modifications, Env is trafficked by the 
secretory pathway to reach the plasma membrane. Once on the plasma membrane, Env is 
incorporated into assembling virus particles. Although poorly understood, the process of 
Env incorporation is known to depend upon specific interactions between the cytoplasmic 
tail of Env and certain residues in the MA domain of Gag in some cell-types [60, 61] 
(Figure 1.2). 
 Although Gag is necessary and sufficient for the production of spherical virus 
particles of approximately 100 nm in diameter, which contain viral genomic RNA, Env 
glycoprotein, and other host and viral proteins, it is unable to mediate scission of viral 
and cellular membranes without the participation of a family of cellular proteins which 
constitute the endosomal sorting complex required for transport (ESCRT) [62, 63]. 
 This ESCRT complex is a large assembly of predominantly cytosolic proteins 
which, upon activation, can polymerize and assemble onto intracellular membranes and 
facilitate membrane scission. This process usually occurs when ESCRT proteins are 
recruited in sequential fashion to ubiquitinylated, transmembrane proteins on the 
cytoplasmic face of multivescicular body (MVB) membranes [64]. The ESCRT complex 
has also been shown to participate in membrane scission during cytokinesis, and is 
essential for cell division [65]. While assembly of retroviruses occurs at the plasma 
membrane in most cell types, it is topologically equivalent to the processes described 
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above, all of which involve budding in a direction away from the cytoplasm. For this 
reason, many viruses such as HIV-1 have evolved to co-opt the ESCRT machinery during 
viral budding. 
 Most ESCRT-dependent processes involve sequential recruitment of four 
complexes, termed ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III.  ESCRT-0 is 
primarily responsible for cargo recognition followed by recruitment of ESCRT-I. 
ESCRT-I, specifically the Tumor susceptibility gene 101 protein (Tsg101), interacts with 
a P(T/S)AP motif on the ESCRT-0 protein Hepatocyte growth factor-regulated tyrosine 
kinase substrate (HRS). This interaction allows the ESCRT-I complex to recruit ESCRT-
II and ESCRT-III complexes sequentially. ESCRT-III proteins then assemble into hetero-
oligomeric complexes which line the neck of the budding vesicle. Finally, a complex 
containing a catalytic AAA-type ATPase, Vacuolar protein sorting-associated protein 4 
(Vps4A/Vps4B), is recruited to polymerized ESCRT-III assemblies and mediates the 
scission of membrane in an ATP-dependent manner [66]. 
 HIV-1 Gag has been shown to recruit ESCRT-III complexes in a manner which is 
independent of ESCRT-0 and ESCRT-II [67]. The late domain of HIV-1, p6, contains a 
P(T/S)AP motif, which allows Gag to mimic the ESCRT-0 complex and interact directly 
with Tsg101 [68-70]. Recruitment of downstream ESCRT-III components by Tsg101 is 
dependent on its interaction with ESCRT-II [67]. Gag also been shown to interact with 
the ESCRT-associated protein Programmed cell death 6-interacting protein (Alix, 
PDCD6-IP, AIP1), which can recruit components of ESCRT-III directly, without a 
requirement for ESCRT-II [71]. Interaction with Alix is mediated by both residues in p6 
[72], as well as the NC domain of Gag [73, 74]. 
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 In chapter 2 of this thesis, I explore the role of the ESCRT machinery in the 
targeting of an antiviral protein to assembling HIV-1 particles. As a conserved feature of 
many enveloped viruses, ESCRT-dependence is both an attractive possible means for the 
cell to recognize and target assembling viruses, as well as a potential target for 
therapeutic intervention of enveloped virus infections. 
 Finally, once virus particles have been successfully detached from the plasma 
membrane of infected cells, they undergo the process of maturation. During maturation, 
the Gag and GagPol precursor poly-proteins are cleaved by the viral protease enzyme 
(PR) into their individual domains, as well as the removal of two spacer peptides from 
Gag (Sp1 and Sp2 or p2 and p1). This processing results in generation of mature virus 
particles containing MA (p17), CA (p24), NC (p7), p6, PR (p10), RT (p51), and IN (p34) 
as individual proteins [75]. This process also results in the appearance of the conical 
capsid core characteristic of mature HIV-1 virions [62] (Figure 1.2). Concurrently, the 
Env glycoprotein (gp160) is cleaved by host proteases such as Furin into gp120 and gp41 
subunits which associate through non-covalent interactions [76]. The gp120 subunit is 
responsible for receptor and co-receptor binding, while the transmembrane gp41 subunit 
is responsible for fusion with cell membranes [16]. 
 
Restriction Factors and Viral Countermeasures 
 As a retrovirus, HIV-1 encodes Gag, Pol, and Env which constitute the structural 
proteins and viral enzymes which mediate viral assembly and are essential for 
progression of the viral life cycle. In addition, HIV-1 encodes two small regulatory 
proteins Tat and Rev, which promote transcription of viral genes and nuclear export of 
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unspliced viral RNA respectively. As a lentivirus, HIV-1 also encodes 4 accessory 
proteins; Vif, Vpr, Vpu, and Nef [77] (Figure 1.1). While these proteins are not necessary 
for virus production in vitro in immortalized cell lines, they are necessary for efficient 
virus replication in primary cells such as T lymphocytes and monocyte-derived 
macrophages, and are believed to play important roles within the context of disease 
progression in vivo [78, 79]. One prominent example of this is the Nef protein, which 
was initially termed negative factor because of its dispensability in cell culture models 
[78, 80]. It has since been shown that Nef greatly enhances virus replication in vivo [81]. 
 It is well known that retroviral tropism is highly species-specific. Nearly every 
primate species examined has been found to harbor distinct retroviruses [82]. This 
exquisite specificity is thought to arise from the presence of specific antiviral proteins, 
termed restriction factors, which limit viral replication in a highly species- and virus-
specific manner. While these proteins may serve other functions, they are thought to be 
primarily antiviral in nature [83]. To be defined as a restriction factor, candidate proteins 
must meet several criteria. Their expression must be induced by interferon in non-
immune cells, which is a classic hallmark of antiviral factors. They must be able to limit 
viral replication, and confer a restrictive phenotype when expressed in otherwise 
permissive cell types. They must undergo positive selection as host organisms adapt to 
the presence of viral infections. Finally, many restriction factors are also targeted for 
destruction or inhibition by viral proteins or countermeasures [84-86] (Figure 1.2). 
 In recent years, the functions of the 4 accessory proteins of HIV-1 have been 
increasingly linked with the ability of HIV-1 to evade host restriction factors and 
replicate efficiently [83]. The most well studied of these, Nef, has several important 
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activities which are all related to the ability of HIV-1 to avoid immune detection within 
infected cells. Upon infection Nef is able to extensively modify many cellular pathways, 
most importantly the down-modulation of CD4 and MHC class I from the cell surface 
through the cooperation of cellular cofactors including clathrin adapters [79]. In the case 
of CD4, this down-regulation is thought to both inhibit re-infection by additional viruses, 
as well as promote viral escape from the cell surface. By down-modulating MHC class I 
from the cell surface, Nef interferes with the ability of infected cells to present viral 
antigens and thereby escape killing by cytotoxic T lymphocytes [87, 88] (Figure 1.2). 
 The viral infectivity factor (Vif) protein of HIV-1 has been found to interact with 
and induce the degradation of certain members of the apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like family of proteins [89]. Of these, APOBEC-3G, and -
3F proteins are specifically incorporated into HIV-1 virions and induce hypermutations in 
the viral genome during the process of reverse transcription through their enzymatic 
activity as cytidine deaminases. By deaminating cytidine residues to uracil on the minus 
strand of viral cDNA, which corresponds to guanine to thymine changes on the positive, 
coding strand. The result of which is the introduction of stop codons or other deleterious 
amino acid substitutions which are detrimental to viral replication [90, 91]. It should also 
be noted that APOBEC proteins can also interfere with the process of reverse 
transcription through deamination-independent mechanisms [92] (Figure 1.2). 
 As with Nef and Vif, the viral protein R (Vpr) of HIV-1 has also been shown to 
perturb cellular processes and promote viral replication. Although the exact function of 
Vpr remains to be elucidated, it is known to be particularly important in macrophages 
[93]. As non-dividing, terminally differentiated cells, macrophages present a particularly 
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difficult environment for viral replication. This is due to limitation of certain resources in 
these cells, as well as the presence of many innate immune sensors which detect and 
inhibit viral replication. However, unlike other retroviruses, lentiviruses such as HIV-1 
possess the unique ability to replicate within terminally differentiated cells. This ability is 
likely due in large part to the activities of Vpr, which is required for efficient viral 
replication in macrophages and dendritic cells [94]. Thusfar, Vpr has been observed to 
induce cell cycle arrest [95], modulate apoptosis [96, 97], activate the ATM and ATR 
DNA damage responses [98-100], induce expression of NK cell ligands [100, 101],and 
degrade the DNA uracil glycosylase UNG2 through interaction with DCAF1 [102]. 
Collectively, these activities or Vpr likely promote viral replication, particularly in 
terminally differentiated cells through creating an intracellular environment more 
conducive for reverse transcription to take place [94] (Figure 1.2). 
 Of great interest recently has been the discovery of a novel restriction factor, 
sterile alpha motif domain and HD domain-containing protein 1 (SAMHD1). This protein 
is present in most cells, but is thought to be active only in terminally differentiated cells 
such as macrophages and dendritic cells as well as in resting CD4
+
 T cells. Its primary 
function in these cells is to deplete cellular dNTP pools through its enzymatic nucleotide 
phosphatase activity. With respect to retroviral replication, this activity is also 
detrimental to the synthesis of viral cDNA during reverse transcription. Although HIV-1 
does not appear to be able to antagonize SAMHD1 activity, two closely related viruses, 
HIV-2 and SIV, both express an additional accessory protein Vpx (which appears to have 
been derived from Vpr) which is able to induce degradation of SAMHD1 [103-107]. 
Although the implications of this difference are not entirely clear, it is likely that HIV-1 
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has either not yet evolved the capability to antagonize SAMHD1 or that it has evolved to 
replicate primarily in activated T lymphocytes, in which SAMDH1 is not active, thereby 
making Vpx non-essential for its replication [108, 109] (Figure 1.2). 
 Another family of proteins, the tripartite motif-containing (TRIM) proteins, have 
been identified as antiviral restriction factors, some of which target retroviral capsids 
[110]. In particular TRIM5 from Rhesus macaques and TRIMCyp from Owl monkeys 
have both been shown to potently inhibit replication of HIV-1 [111, 112]. Soon after 
infection, these proteins are able to bind to retroviral capsids, inhibit reverse 
transcription, and accelerate uncoating [113-118]. Although humans also express 
TRIM5, HIV-1 has escaped its restrictive activity though mutation of its capsid domain 
[110] (Figure 1.2). 
 The viral protein U (Vpu) of HIV-1 has also been of great interest recently. 
Although it was long known that Vpu decreases cell-surface expression of CD4 [119] and 
enhances production of virus from certain cell types [120-122], the mechanism of this 
enhancement has only recently become clear. Through the use of heterokaryons, formed 
from fusion of permissive and non-permissive cells, Vpu was shown to reverse the effect 
of some dominant negative factor which is present in non-permissive cells [123]. This 
negative factor was later identified to be BST-2/tetherin, which both inhibits HIV-1 
release and is antagonized by Vpu [124, 125] (Figure 1.2). 
Tetherin is present in all mammals, and exhibits a unique topology with respect to 
all known mammalian proteins. This small protein contains both an N-terminal 
transmembrane domain, as well as a predicted C-terminal glycosylphosphatidylinositol 
(GPI) anchor [126]. Tetherin has been shown to modulate the production of interferon by 
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plasmacytoid dendritic cells, through interaction with the ILT-7 receptor [127, 128], but 
growing evidence supports the hypothesis that its function is primarily antiviral in nature 
[129]. This model is supported by the finding that tetherin knockout mice display no 
obvious morphological abnormalities or immune dysfunction, other than lack of tetherin-
mediated antiviral activity [130]. 
Much is known about the mechanisms by which several viruses counteract 
tetherin antiviral activity. The HIV-1 Vpu protein has been shown to bind directly to 
tetherin through interactions between their transmembrane domains [131]. Vpu has also 
been shown to induce degradation of tetherin through utilization of a cellular ubiquitin-
ligase complex, -TrCP [132, 133]. This interaction has also been shown to result in non-
classical ubiquitination of tetherin [134, 135]. It has also been shown that Vpu is able to 
antagonize tetherin function through other mechanisms which do not involve 
ubiquitination and degradation [136-138]. 
Taken together, these findings have greatly expanded our understanding of how 
the innate immune system acts to limit the replication of viruses at the level of single 
cells. Restriction factors as defined above constitute a network of intrinsic cellular 
immunity which constitute a substantial barrier to viral infection, especially of 
retroviruses such as HIV-1. As successful and persistent pathogens, many viruses have 
evolved mechanisms to evade or inhibit these pathways, and thereby create a permissive 
cellular niche in which to replicate and avoid detection and destruction by the immune 
response [84-86]. 
Despite these detailed insights into tetherin antagonism by different viruses, the 
more fundamental question remains unanswered; how is tetherin recruited to virus 
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assembly sites in the absence of viral antagonism?  While tetherin is known to associate 
intimately with assembling viruses, the mechanism behind this recruitment remains to be 
described [139]. It has been hypothesized by many that recruitment of tetherin to HIV-1 
assembly sites is mediated by its presence in detergent-resistant membranes [126], which 
are also present at HIV-1 assembly sites [42]. In chapter 2 of this thesis, I address 
directly, for the first time, the question of how tetherin is recruited to HIV-1 assembly 
sites. This study has led to the identification of viral and cellular determinants which 
mediate and enhance tetherin recruitment to HIV-1 assembly sites. By understanding the 
fundamental mechanisms by which tetherin is able to sense and target HIV-1, we may 
gain greater insight into the ability of tetherin to broadly inhibit other enveloped viruses. 
We may also be able to design therapeutic strategies which enhance tetherin antiviral 
activity, or inhibit the viral countermeasures which antagonize its function. 
 
Super-Resolution Microscopy Techniques and Applications 
 The interrogation of intact biological systems has been greatly aided by the 
development of fluorescence microscopy techniques. Although inherently limited by 
diffraction, light microscopy allows for the specific labeling of molecules of interest with 
chemical fluorophores or fluorescent proteins. This can be accomplished by a variety of 
different methods including direct fluorophore conjugation to molecules of interest or 
their cognate ligands, immunofluorescence by fluorescently-labeled antibodies, or genetic 
fusion of fluorescent proteins such as green fluorescent protein (GFP) to target proteins 
of interest. While more detailed spatial information can be acquired through the use of 
various electron microscopy techniques, these are severely limited in their ability to label 
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specific molecules, as well as the laborious process of sample preparation [140]. Since 
the discovery of GFP [141] and other related fluorescent proteins from various marine 
organisms [142], these proteins have emerged as powerful tools for fluorescence 
microscopy. 
 Recently, advancements in optics, imaging techniques, and image processing 
algorithms have allowed for the development of various forms of super-resolution 
microscopy. Using these techniques, detailed spatial information about the location of 
single molecules can be obtained well below the diffraction limit of light (~200 nm). 
 There are several obstacles to the localization of single molecules or fluorophores 
with high precision beyond the limits imposed by diffraction. These include the 
sensitivity of detectors to capture sufficient signal from individual fluorophores, the 
separation of true signal from other noise and background fluorescence which may be 
present in the sample, as well as the ability to discriminate individual molecules from 
each other when they are present in high abundance. A variety of strategies can be used 
to circumvent or avoid these problems [143].  
There are several types of super-resolution microscopy, including structured 
illumination microscopy (SIM) [144, 145], stimulated emission depletion microscopy 
(STED) [146-148] , photoactivated localization microscopy (PALM) [149], and 
stochastic optical reconstruction microscopy (STORM/dSTORM) [150, 151]. 
In general terms, localization of individual molecules can be accomplished by 
assuming that the diffraction-limited images created by single fluorophores on a detector 
can be described by an Airy function. Given that these functions closely resemble 
Gaussian functions, they can be fit mathematically, which allows for localization of 
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single fluorophores with extremely high precision (10-20 nm) [143]. More sensitive 
detection of individual fluorophores has been achieved through the development of the 
electron multiplying charge coupled devide (EMCCD). These devices have superior 
sensitivity and speed when compared with conventional charge coupled devices (CCDs) 
[152].  
In order to eliminate excessive background signal and out-of-focus light 
frequently present in biological samples, total internal reflection fluorescence (TIRF) 
illumination is typically used. In TIRF microscopy, a coherent laser excitation source is 
positioned so that it strikes the coverslip at an angle at or below the critical angle (c). 
When introduced in this way, excitation light is internally reflected within the coverslip, 
rather than being refracted into the sample. Through interaction with the surface of the 
coverslip immediately opposed to the sample, an evanescent wave is generated which 
penetrates only 50-200 nm into the sample, depending on the wavelength used and the 
angle of incidence [153] (Figure 1.4). This technique is particularly well suited for the 
study of processes which take place at the plasma membrane, and is frequently used for 
super-resolution microscopy methods because of the minimal contribution of background 
and out-of-focus fluorescence [143]. 
In order to distinguish single fluorophores when present at a high density, a subset 
of total fluorophores in the sample must be emitting fluorescence at any given time. This 
can be accomplished through the use of periodic illumination patters (SIM) [144, 145] or 
through stimulated emission of fluorophores (STED) [146-148]. Alternatively, certain 





Figure 1.4. Explanation of total internal reflection microscopy (TIRF). 
In conventional, or widefield illumination microscopy, excitation light is directed perpendicular to the 
coverslip. This results in illumination of a large section of the sample, which also results in out-of-focus 
fluorescence and background signals. In TIRF illumination, the excitation beam strikes the coverslip at an 
angle which is less than the critical angle or c. The critical angle is defined as the angle at which incident 
light is completely reflected within the coverslip, rather than being refracted into the sample. When total 
internal reflection has been achieved, an evanescent wave is generated at the glass–sample interface with 
the same wavelength as the excitation source. This allows for selective illumination of fluorophores which 
are very near the interface. This penetration depth is usually 50–200 nm, depending on the incident angle 
and wavelength used. 
 
or reversible photo-blinking. In the case of organic cyanine and rhodamine based 
fluorophores, reversible conversion between bright and dark states can be accomplished 
by placing samples in a reducing buffer (Figure 1.5). 
Conventional STORM utilizes fluorophore pairs conjugated to molecules of 
interest, which are activated and deactivated by different wavelengths of light to 
accomplish reversible photoconversion [150]. Recently, an improved technique referred 
to as direct-STORM (dSTORM) has been developed, which utilizes single fluorophores, 
such as Alexa Fluor 647, which can be both activated and deactivated by a single 
wavelength of light (Figure 1.5). This technique is much easier to accomplish because of 
the ease of single fluorophore-conjugation, as well as the use of less-complicated optical 
systems [151, 154]. 
Photoactivatable fluorescent proteins such as photoactivatable GFP (PA-GFP) and 





Figure 1.5. Schematic overview of dSTORM and PALM techniques used in this thesis.  
(A) Under normal, oxidizing conditions excitation by high intensity laser light results in irreversible 
photobleaching of fluorophores such as Alexa Fluor 647, due to oxidation of the fluorophore. (B) Under 
reducing conditions, fluorophores can transition many times between their bright, fluorescent state and a 
dark state, because oxygen is not available for oxidation of the fluorophore. (C,D) Similarly, fluorescent 
proteins such as mEos3.2 (mEos2 is depicted here, PDB: 3S05) can be photoconverted from a green-
emitting state to a red-emitting state by low levels of UV (405 nm) laser stimulation. (C) Under normal 
conditions, excitation of the red state by high intensity laser light results in irreversible photobleaching of 
the chromophore. (D) Under reducing conditions, however, mEos3.2 behaves in a similar way to Alexa 
Fluor 647, undergoing reversible photo-blinking between its bright, fluorescent state and a dark state. 
 
by ultraviolet (UV) light (PALM). Other fluorescent proteins such as EosFP derivatives, 
Dendra, Dronpa, Kaede, and others are capable of being converted from one fluorescent 
state to another [155]. When combined with rapid photobleaching by high intensity 
excitation, a subset of fluorophores can be selectively imaged over time to generate a 
reconstructed image representing the ensemble of all fluorphores, each localized with 
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high precision [143].  Recently it has been reported that EosFP-derived proteins, in 
particular, exhibit superior spectral properties which make them ideally suited to super-
resolution microscopy methods [149, 156, 157]. It has also been shown that these 
proteins are able to undergo reversible photoblinking under reducing conditions [158] 
(Figure 1.5).  
For the studies presented in chapters 2 and 3 of this thesis, we chose to utilize a 
system which combines the advantages of PALM and dSTORM. In particular, we 
utilized Alexa Fluor 647 and the monomeric, photoconvertible fluorescent protein 
mEos3.2 for these experiments because of their superior spectral properties and 
compatibility with reducing buffers [154, 157, 158]. 
Given that many viruses such as HIV-1 are smaller than the diffraction limit of 
conventional light microscopy (~100 nm diameter), super-resolution localization 
microscopy offers a powerful method to study viral assembly and virus-host interactions 
at the level of single virus particles with unprecedented detail. Thus far, various super-
resolution microscopy techniques have been employed to study interactions between 
tetherin and HIV-1 assembly sites [159, 160], HIV-1 virion morphology [149, 161, 162], 
HIV-1 protein distribution during virus entry [163, 164], and Env incorporation to virus 
particles [61]. Super-resolution microscopy has also been applied to study influenza HA 
protein [165], vaccinia virus [166, 167], and RNA virus replication complexes in plants 
[168].  
In work presented in this thesis, I have applied super-resolution localization 
microscopy techniques to identify and characterize different mechanisms by which host 




1. Barre-Sinoussi, F., et al., Isolation of a T-lymphotropic retrovirus from a patient 
at risk for acquired immune deficiency syndrome (AIDS). Science, 1983. 
220(4599): p. 868-71. 
2. Gallo, R.C., et al., Isolation of human T-cell leukemia virus in acquired immune 
deficiency syndrome (AIDS). Science, 1983. 220(4599): p. 865-7. 
3. Montagnier, L., 25 years after HIV discovery: prospects for cure and vaccine. 
Virology, 2010. 397(2): p. 248-54. 
4. WHO. Global summary of the AIDS epidemic.  2011. 
5. Pantaleo, G. and Y. Levy, Vaccine and immunotherapeutic interventions. Curr 
Opin HIV AIDS, 2013. 8(3): p. 236-42. 
6. Vella, S., et al., The history of antiretroviral therapy and of its implementation in 
resource-limited areas of the world. AIDS, 2012. 26(10): p. 1231-41. 
7. Adachi, A., et al., Production of acquired immunodeficiency syndrome-associated 
retrovirus in human and nonhuman cells transfected with an infectious molecular 
clone. J Virol, 1986. 59(2): p. 284-91. 
8. Lassen, K., et al., The multifactorial nature of HIV-1 latency. Trends Mol Med, 
2004. 10(11): p. 525-31. 
9. Pasman, L., The complication of coinfection. Yale J Biol Med, 2012. 85(1): p. 
127-32. 
10. Cloyd, M.W., J.J. Chen, and I. Wang, How does HIV cause AIDS? The homing 
theory. Mol Med Today, 2000. 6(3): p. 108-11. 
11. Gougeon, M.L. and L. Montagnier, Apoptosis in AIDS. Science, 1993. 260(5112): 
p. 1269-70. 
12. Onafuwa-Nuga, A., L.A. McNamara, and K.L. Collins, Towards a cure for HIV: 
the identification and characterization of HIV reservoirs in optimally treated 
people. Cell Res, 2010. 20(11): p. 1185-7. 
13. Xing, S. and R.F. Siliciano, Targeting HIV latency: pharmacologic strategies 
toward eradication. Drug Discov Today, 2012. 
14. Levy, J.A., et al., Isolation of lymphocytopathic retroviruses from San Francisco 
patients with AIDS. Science, 1984. 225(4664): p. 840-2. 
15. Zhang, C.W., et al., Expression, purification, and characterization of recombinant 
HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is 
24 
 
sufficient to maintain the retroviral envelope glycoprotein as a trimer. J Biol 
Chem, 2001. 276(43): p. 39577-85. 
16. Blumenthal, R., S. Durell, and M. Viard, HIV entry and envelope glycoprotein-
mediated fusion. J Biol Chem, 2012. 287(49): p. 40841-9. 
17. Barat, C., et al., HIV-1 reverse transcriptase specifically interacts with the 
anticodon domain of its cognate primer tRNA. EMBO J, 1989. 8(11): p. 3279-85. 
18. Hu, W.S. and S.H. Hughes, HIV-1 reverse transcription. Cold Spring Harb 
Perspect Med, 2012. 2(10). 
19. Krishnan, L. and A. Engelman, Retroviral integrase proteins and HIV-1 DNA 
integration. J Biol Chem, 2012. 287(49): p. 40858-66. 
20. Vink, C. and R.H. Plasterk, The human immunodeficiency virus integrase protein. 
Trends Genet, 1993. 9(12): p. 433-8. 
21. Stoltzfus, C.M., Chapter 1. Regulation of HIV-1 alternative RNA splicing and its 
role in virus replication. Adv Virus Res, 2009. 74: p. 1-40. 
22. Debaisieux, S., et al., The ins and outs of HIV-1 Tat. Traffic, 2012. 13(3): p. 355-
63. 
23. Garcia, J.A., et al., Functional domains required for tat-induced transcriptional 
activation of the HIV-1 long terminal repeat. EMBO J, 1988. 7(10): p. 3143-7. 
24. Kao, S.Y., et al., Anti-termination of transcription within the long terminal repeat 
of HIV-1 by tat gene product. Nature, 1987. 330(6147): p. 489-93. 
25. Feng, S. and E.C. Holland, HIV-1 tat trans-activation requires the loop sequence 
within tar. Nature, 1988. 334(6178): p. 165-7. 
26. Laspia, M.F., A.P. Rice, and M.B. Mathews, HIV-1 Tat protein increases 
transcriptional initiation and stabilizes elongation. Cell, 1989. 59(2): p. 283-92. 
27. Selby, M.J., et al., Structure, sequence, and position of the stem-loop in tar 
determine transcriptional elongation by tat through the HIV-1 long terminal 
repeat. Genes Dev, 1989. 3(4): p. 547-58. 
28. Long, K.S. and D.M. Crothers, Characterization of the solution conformations of 
unbound and Tat peptide-bound forms of HIV-1 TAR RNA. Biochemistry, 1999. 
38(31): p. 10059-69. 
29. Suhasini, M. and T.R. Reddy, Cellular proteins and HIV-1 Rev function. Curr 
HIV Res, 2009. 7(1): p. 91-100. 
25 
 
30. Malim, M.H., et al., The HIV-1 rev trans-activator acts through a structured 
target sequence to activate nuclear export of unspliced viral mRNA. Nature, 1989. 
338(6212): p. 254-7. 
31. Heaphy, S., et al., HIV-1 regulator of virion expression (Rev) protein binds to an 
RNA stem-loop structure located within the Rev response element region. Cell, 
1990. 60(4): p. 685-93. 
32. Kjems, J., et al., Structural analysis of the interaction between the human 
immunodeficiency virus Rev protein and the Rev response element. Proc Natl 
Acad Sci U S A, 1991. 88(3): p. 683-7. 
33. Shioda, T. and H. Shibuta, Production of human immunodeficiency virus (HIV)-
like particles from cells infected with recombinant vaccinia viruses carrying the 
gag gene of HIV. Virology, 1990. 175(1): p. 139-48. 
34. Wilson, W., et al., HIV expression strategies: ribosomal frameshifting is directed 
by a short sequence in both mammalian and yeast systems. Cell, 1988. 55(6): p. 
1159-69. 
35. Ganser-Pornillos, B.K., M. Yeager, and O. Pornillos, Assembly and architecture 
of HIV. Adv Exp Med Biol, 2012. 726: p. 441-65. 
36. Gottlinger, H.G., J.G. Sodroski, and W.A. Haseltine, Role of capsid precursor 
processing and myristoylation in morphogenesis and infectivity of human 
immunodeficiency virus type 1. Proc Natl Acad Sci U S A, 1989. 86(15): p. 5781-
5. 
37. Ono, A., et al., Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag 
targeting to the plasma membrane. Proc Natl Acad Sci U S A, 2004. 101(41): p. 
14889-94. 
38. Saad, J.S., et al., Structural basis for targeting HIV-1 Gag proteins to the plasma 
membrane for virus assembly. Proc Natl Acad Sci U S A, 2006. 103(30): p. 
11364-9. 
39. Chukkapalli, V., et al., Interaction between the human immunodeficiency virus 
type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is 
essential for efficient gag membrane binding. J Virol, 2008. 82(5): p. 2405-17. 
40. Ono, A., HIV-1 Assembly at the Plasma Membrane: Gag Trafficking and 
Localization. Future Virol, 2009. 4(3): p. 241-257. 
41. Chukkapalli, V. and A. Ono, Molecular determinants that regulate plasma 
membrane association of HIV-1 Gag. J Mol Biol, 2011. 410(4): p. 512-24. 
42. Ono, A. and E.O. Freed, Plasma membrane rafts play a critical role in HIV-1 
assembly and release. Proc Natl Acad Sci U S A, 2001. 98(24): p. 13925-30. 
26 
 
43. Nydegger, S., et al., Mapping of tetraspanin-enriched microdomains that can 
function as gateways for HIV-1. J Cell Biol, 2006. 173(5): p. 795-807. 
44. Jolly, C. and Q.J. Sattentau, Human immunodeficiency virus type 1 assembly, 
budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma 
membrane domains. J Virol, 2007. 81(15): p. 7873-84. 
45. Garcia, E., D.S. Nikolic, and V. Piguet, HIV-1 replication in dendritic cells 
occurs through a tetraspanin-containing compartment enriched in AP-3. Traffic, 
2008. 9(2): p. 200-14. 
46. Grigorov, B., et al., A role for CD81 on the late steps of HIV-1 replication in a 
chronically infected T cell line. Retrovirology, 2009. 6: p. 28. 
47. Thali, M., Tetraspanin functions during HIV-1 and influenza virus replication. 
Biochem Soc Trans, 2011. 39(2): p. 529-31. 
48. Llewellyn, G.N., et al., Nucleocapsid promotes localization of HIV-1 gag to 
uropods that participate in virological synapses between T cells. PLoS Pathog, 
2010. 6(10): p. e1001167. 
49. Llewellyn, G.N., et al., HIV-1 Gag Associates with Specific Uropod-Directed 
Microdomains in a Manner Dependent on its MA Highly Basic Region. J Virol, 
2013. 
50. Krementsov, D.N., et al., HIV-1 assembly differentially alters dynamics and 
partitioning of tetraspanins and raft components. Traffic, 2010. 11(11): p. 1401-
14. 
51. Hogue, I.B., et al., Gag induces the coalescence of clustered lipid rafts and 
tetraspanin-enriched microdomains at HIV-1 assembly sites on the plasma 
membrane. J Virol, 2011. 85(19): p. 9749-66. 
52. Burniston, M.T., et al., Human immunodeficiency virus type 1 Gag polyprotein 
multimerization requires the nucleocapsid domain and RNA and is promoted by 
the capsid-dimer interface and the basic region of matrix protein. J Virol, 1999. 
73(10): p. 8527-40. 
53. Hogue, I.B., A. Hoppe, and A. Ono, Quantitative fluorescence resonance energy 
transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-
Gag interaction: relative contributions of the CA and NC domains and membrane 
binding. J Virol, 2009. 83(14): p. 7322-36. 
54. Bharat, T.A., et al., Structure of the immature retroviral capsid at 8 A resolution 
by cryo-electron microscopy. Nature, 2012. 487(7407): p. 385-9. 
55. Datta, S.A., et al., On the role of the SP1 domain in HIV-1 particle assembly: a 
molecular switch? J Virol, 2011. 85(9): p. 4111-21. 
27 
 
56. Skripkin, E., et al., Identification of the primary site of the human 
immunodeficiency virus type 1 RNA dimerization in vitro. Proc Natl Acad Sci U S 
A, 1994. 91(11): p. 4945-9. 
57. Lu, K., X. Heng, and M.F. Summers, Structural determinants and mechanism of 
HIV-1 genome packaging. J Mol Biol, 2011. 410(4): p. 609-33. 
58. Lu, K., et al., NMR detection of structures in the HIV-1 5'-leader RNA that 
regulate genome packaging. Science, 2011. 334(6053): p. 242-5. 
59. South, T.L. and M.F. Summers, Zinc- and sequence-dependent binding to nucleic 
acids by the N-terminal zinc finger of the HIV-1 nucleocapsid protein: NMR 
structure of the complex with the Psi-site analog, dACGCC. Protein Sci, 1993. 
2(1): p. 3-19. 
60. Postler, T.S. and R.C. Desrosiers, The tale of the long tail: the cytoplasmic 
domain of HIV-1 gp41. J Virol, 2013. 87(1): p. 2-15. 
61. Muranyi, W., et al., Super-resolution microscopy reveals specific recruitment of 
HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-
terminal tail. PLoS Pathog, 2013. 9(2): p. e1003198. 
62. Sundquist, W.I. and H.G. Krausslich, HIV-1 assembly, budding, and maturation. 
Cold Spring Harb Perspect Med, 2012. 2(7): p. a006924. 
63. Garrus, J.E., et al., Tsg101 and the vacuolar protein sorting pathway are essential 
for HIV-1 budding. Cell, 2001. 107(1): p. 55-65. 
64. McCullough, J., L.A. Colf, and W.I. Sundquist, Membrane Fission Reactions of 
the Mammalian ESCRT Pathway. Annu Rev Biochem, 2013. 
65. Morita, E., et al., Human ESCRT and ALIX proteins interact with proteins of the 
midbody and function in cytokinesis. EMBO J, 2007. 26(19): p. 4215-27. 
66. Hurley, J.H. and P.I. Hanson, Membrane budding and scission by the ESCRT 
machinery: it's all in the neck. Nat Rev Mol Cell Biol, 2010. 11(8): p. 556-66. 
67. von Schwedler, U.K., et al., The protein network of HIV budding. Cell, 2003. 
114(6): p. 701-13. 
68. Pornillos, O., et al., HIV Gag mimics the Tsg101-recruiting activity of the human 
Hrs protein. J Cell Biol, 2003. 162(3): p. 425-34. 
69. VerPlank, L., et al., Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, 
binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A, 2001. 
98(14): p. 7724-9. 
28 
 
70. Pornillos, O., et al., Structure of the Tsg101 UEV domain in complex with the 
PTAP motif of the HIV-1 p6 protein. Nat Struct Biol, 2002. 9(11): p. 812-7. 
71. Dowlatshahi, D.P., et al., ALIX is a Lys63-specific polyubiquitin binding protein 
that functions in retrovirus budding. Dev Cell, 2012. 23(6): p. 1247-54. 
72. Strack, B., et al., AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 
functioning in virus budding. Cell, 2003. 114(6): p. 689-99. 
73. Popov, S., et al., Human immunodeficiency virus type 1 Gag engages the Bro1 
domain of ALIX/AIP1 through the nucleocapsid. J Virol, 2008. 82(3): p. 1389-98. 
74. Dussupt, V., et al., Basic residues in the nucleocapsid domain of Gag are critical 
for late events of HIV-1 budding. J Virol, 2011. 85(5): p. 2304-15. 
75. Konvalinka, J., et al., Proteolytic processing of particle-associated retroviral 
polyproteins by homologous and heterologous viral proteinases. Eur J Biochem, 
1995. 228(1): p. 191-8. 
76. Nakayama, K., Furin: a mammalian subtilisin/Kex2p-like endoprotease involved 
in processing of a wide variety of precursor proteins. Biochem J, 1997. 327 ( Pt 
3): p. 625-35. 
77. Malim, M.H. and M. Emerman, HIV-1 accessory proteins--ensuring viral survival 
in a hostile environment. Cell Host Microbe, 2008. 3(6): p. 388-98. 
78. Nomaguchi, M., et al., Species tropism of HIV-1 modulated by viral accessory 
proteins. Front Microbiol, 2012. 3: p. 267. 
79. Nishino, Y., et al., Human immunodeficiency virus type 1 vif, vpr, and vpu 
mutants can produce persistently infected cells. Arch Virol, 1991. 120(3-4): p. 
181-92. 
80. Niederman, T.M., W. Hu, and L. Ratner, Simian immunodeficiency virus negative 
factor suppresses the level of viral mRNA in COS cells. J Virol, 1991. 65(7): p. 
3538-46. 
81. Zou, W., et al., Nef functions in BLT mice to enhance HIV-1 replication and 
deplete CD4+CD8+ thymocytes. Retrovirology, 2012. 9: p. 44. 
82. Fauci, A.S. and R.C. Desrosiers, Pathogenesis of HIV and SIV. 1997. 
83. Hatziioannou, T. and P.D. Bieniasz, Antiretroviral restriction factors. Curr Opin 
Virol, 2011. 1(6): p. 526-32. 
84. Harris, R.S., J.F. Hultquist, and D.T. Evans, The restriction factors of human 
immunodeficiency virus. J Biol Chem, 2012. 287(49): p. 40875-83. 
29 
 
85. Duggal, N.K. and M. Emerman, Evolutionary conflicts between viruses and 
restriction factors shape immunity. Nat Rev Immunol, 2012. 12(10): p. 687-95. 
86. Malim, M.H. and P.D. Bieniasz, HIV Restriction Factors and Mechanisms of 
Evasion. Cold Spring Harb Perspect Med, 2012. 2(5): p. a006940. 
87. Wonderlich, E.R., J.A. Leonard, and K.L. Collins, HIV immune evasion 
disruption of antigen presentation by the HIV Nef protein. Adv Virus Res, 2011. 
80: p. 103-27. 
88. Collins, K.L., et al., HIV-1 Nef protein protects infected primary cells against 
killing by cytotoxic T lymphocytes. Nature, 1998. 391(6665): p. 397-401. 
89. Sheehy, A.M., et al., Isolation of a human gene that inhibits HIV-1 infection and 
is suppressed by the viral Vif protein. Nature, 2002. 418(6898): p. 646-50. 
90. Romani, B., S. Engelbrecht, and R.H. Glashoff, Antiviral roles of APOBEC 
proteins against HIV-1 and suppression by Vif. Arch Virol, 2009. 154(10): p. 
1579-88. 
91. Mangeat, B., et al., Broad antiretroviral defence by human APOBEC3G through 
lethal editing of nascent reverse transcripts. Nature, 2003. 424(6944): p. 99-103. 
92. Shindo, K., et al., The enzymatic activity of CEM15/Apobec-3G is essential for the 
regulation of the infectivity of HIV-1 virion but not a sole determinant of its 
antiviral activity. J Biol Chem, 2003. 278(45): p. 44412-6. 
93. Subbramanian, R.A., et al., Human immunodeficiency virus type 1 Vpr is a 
positive regulator of viral transcription and infectivity in primary human 
macrophages. J Exp Med, 1998. 187(7): p. 1103-11. 
94. Mashiba, M. and K.L. Collins, Molecular mechanisms of HIV immune evasion of 
the innate immune response in myeloid cells. Viruses, 2013. 5(1): p. 1-14. 
95. Jowett, J.B., et al., The human immunodeficiency virus type 1 vpr gene arrests 
infected T cells in the G2 + M phase of the cell cycle. J Virol, 1995. 69(10): p. 
6304-13. 
96. Stewart, S.A., et al., Human immunodeficiency virus type 1 Vpr induces apoptosis 
following cell cycle arrest. J Virol, 1997. 71(7): p. 5579-92. 
97. Conti, L., et al., The HIV-1 vpr protein acts as a negative regulator of apoptosis 
in a human lymphoblastoid T cell line: possible implications for the pathogenesis 
of AIDS. J Exp Med, 1998. 187(3): p. 403-13. 
98. Poon, B., et al., Human immunodeficiency virus type 1 vpr gene induces 
phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. 
J Virol, 1997. 71(5): p. 3961-71. 
30 
 
99. Ward, J., et al., HIV-1 Vpr triggers natural killer cell-mediated lysis of infected 
cells through activation of the ATR-mediated DNA damage response. PLoS 
Pathog, 2009. 5(10): p. e1000613. 
100. Norman, J.M., et al., The antiviral factor APOBEC3G enhances the recognition of 
HIV-infected primary T cells by natural killer cells. Nat Immunol, 2011. 12(10): 
p. 975-83. 
101. Richard, J., et al., HIV-1 Vpr up-regulates expression of ligands for the activating 
NKG2D receptor and promotes NK cell-mediated killing. Blood, 2010. 115(7): p. 
1354-63. 
102. Ahn, J., et al., HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a 
substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for 
proteasome-dependent degradation. J Biol Chem, 2010. 285(48): p. 37333-41. 
103. Laguette, N., et al., SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 
restriction factor counteracted by Vpx. Nature, 2011. 474(7353): p. 654-7. 
104. Hrecka, K., et al., Vpx relieves inhibition of HIV-1 infection of macrophages 
mediated by the SAMHD1 protein. Nature, 2011. 474(7353): p. 658-61. 
105. Goldstone, D.C., et al., HIV-1 restriction factor SAMHD1 is a deoxynucleoside 
triphosphate triphosphohydrolase. Nature, 2011. 480(7377): p. 379-82. 
106. Powell, R.D., et al., Aicardi-Goutieres syndrome gene and HIV-1 restriction 
factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J 
Biol Chem, 2011. 286(51): p. 43596-600. 
107. Berger, A., et al., SAMHD1-deficient CD14+ cells from individuals with Aicardi-
Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog, 
2011. 7(12): p. e1002425. 
108. Baldauf, H.M., et al., SAMHD1 restricts HIV-1 infection in resting CD4(+) T 
cells. Nat Med, 2012. 18(11): p. 1682-7. 
109. Laguette, N. and M. Benkirane, How SAMHD1 changes our view of viral 
restriction. Trends Immunol, 2012. 33(1): p. 26-33. 
110. Grutter, M.G. and J. Luban, TRIM5 structure, HIV-1 capsid recognition, and 
innate immune signaling. Curr Opin Virol, 2012. 2(2): p. 142-50. 
111. Stremlau, M., et al., The cytoplasmic body component TRIM5alpha restricts HIV-
1 infection in Old World monkeys. Nature, 2004. 427(6977): p. 848-53. 
112. Sayah, D.M., et al., Cyclophilin A retrotransposition into TRIM5 explains owl 
monkey resistance to HIV-1. Nature, 2004. 430(6999): p. 569-73. 
31 
 
113. Diaz-Griffero, F., et al., Requirements for capsid-binding and an effector function 
in TRIMCyp-mediated restriction of HIV-1. Virology, 2006. 351(2): p. 404-19. 
114. Ganser-Pornillos, B.K., et al., Hexagonal assembly of a restricting TRIM5alpha 
protein. Proc Natl Acad Sci U S A, 2011. 108(2): p. 534-9. 
115. Biris, N., et al., Structure of the rhesus monkey TRIM5alpha PRYSPRY domain, 
the HIV capsid recognition module. Proc Natl Acad Sci U S A, 2012. 109(33): p. 
13278-83. 
116. Roa, A., et al., RING domain mutations uncouple TRIM5alpha restriction of HIV-
1 from inhibition of reverse transcription and acceleration of uncoating. J Virol, 
2012. 86(3): p. 1717-27. 
117. Kim, J., C. Tipper, and J. Sodroski, Role of TRIM5alpha RING domain E3 
ubiquitin ligase activity in capsid disassembly, reverse transcription blockade, 
and restriction of simian immunodeficiency virus. J Virol, 2011. 85(16): p. 8116-
32. 
118. Tareen, S.U. and M. Emerman, Human Trim5alpha has additional activities that 
are uncoupled from retroviral capsid recognition. Virology, 2011. 409(1): p. 113-
20. 
119. Geleziunas, R., S. Bour, and M.A. Wainberg, Cell surface down-modulation of 
CD4 after infection by HIV-1. FASEB J, 1994. 8(9): p. 593-600. 
120. Gottlinger, H.G., et al., Vpu protein of human immunodeficiency virus type 1 
enhances the release of capsids produced by gag gene constructs of widely 
divergent retroviruses. Proc Natl Acad Sci U S A, 1993. 90(15): p. 7381-5. 
121. Geraghty, R.J., et al., Cell type-dependence for Vpu function. J Med Primatol, 
1994. 23(2-3): p. 146-50. 
122. Schubert, U., K.A. Clouse, and K. Strebel, Augmentation of virus secretion by the 
human immunodeficiency virus type 1 Vpu protein is cell type independent and 
occurs in cultured human primary macrophages and lymphocytes. J Virol, 1995. 
69(12): p. 7699-711. 
123. Varthakavi, V., et al., Viral protein U counteracts a human host cell restriction 
that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A, 2003. 100(25): 
p. 15154-9. 
124. Neil, S.J., T. Zang, and P.D. Bieniasz, Tetherin inhibits retrovirus release and is 
antagonized by HIV-1 Vpu. Nature, 2008. 451(7177): p. 425-30. 
125. Van Damme, N., et al., The interferon-induced protein BST-2 restricts HIV-1 
release and is downregulated from the cell surface by the viral Vpu protein. Cell 
Host Microbe, 2008. 3(4): p. 245-52. 
32 
 
126. Kupzig, S., et al., Bst-2/HM1.24 is a raft-associated apical membrane protein 
with an unusual topology. Traffic, 2003. 4(10): p. 694-709. 
127. Cao, W., et al., Regulation of TLR7/9 responses in plasmacytoid dendritic cells by 
BST2 and ILT7 receptor interaction. J Exp Med, 2009. 206(7): p. 1603-14. 
128. Cao, W. and L. Bover, Signaling and ligand interaction of ILT7: receptor-
mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev, 
2010. 234(1): p. 163-76. 
129. Swiecki, M., N.S. Omattage, and T.J. Brett, BST-2/tetherin: structural biology, 
viral antagonism, and immunobiology of a potent host antiviral factor. Mol 
Immunol, 2013. 54(2): p. 132-9. 
130. Liberatore, R.A. and P.D. Bieniasz, Tetherin is a key effector of the antiretroviral 
activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A, 2011. 
108(44): p. 18097-101. 
131. Vigan, R. and S.J. Neil, Determinants of tetherin antagonism in the 
transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. 
J Virol, 2010. 84(24): p. 12958-70. 
132. Mitchell, R.S., et al., Vpu antagonizes BST-2-mediated restriction of HIV-1 
release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog, 2009. 5(5): 
p. e1000450. 
133. Mangeat, B., et al., HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by 
binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog, 
2009. 5(9): p. e1000574. 
134. Gustin, J.K., et al., Ubiquitination of BST-2 protein by HIV-1 Vpu protein does 
not require lysine, serine, or threonine residues within the BST-2 cytoplasmic 
domain. J Biol Chem, 2012. 287(18): p. 14837-50. 
135. Tokarev, A.A., J. Munguia, and J.C. Guatelli, Serine-threonine ubiquitination 
mediates downregulation of BST-2/tetherin and relief of restricted virion release 
by HIV-1 Vpu. J Virol, 2011. 85(1): p. 51-63. 
136. Dube, M., et al., Antagonism of tetherin restriction of HIV-1 release by Vpu 
involves binding and sequestration of the restriction factor in a perinuclear 
compartment. PLoS Pathog, 2010. 6(4): p. e1000856. 
137. Tervo, H.M., et al., beta-TrCP is dispensable for Vpu's ability to overcome the 




138. Schmidt, S., et al., HIV-1 Vpu blocks recycling and biosynthetic transport of the 
intrinsic immunity factor CD317/tetherin to overcome the virion release 
restriction. MBio, 2011. 2(3): p. e00036-11. 
139. Fitzpatrick, K., et al., Direct restriction of virus release and incorporation of the 
interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog, 2010. 6(3): 
p. e1000701. 
140. Moerner, W.E., Microscopy beyond the diffraction limit using actively controlled 
single molecules. J Microsc, 2012. 246(3): p. 213-20. 
141. Shimomura, O., F.H. Johnson, and Y. Saiga, Extraction, purification and 
properties of aequorin, a bioluminescent protein from the luminous 
hydromedusan, Aequorea. J Cell Comp Physiol, 1962. 59: p. 223-39. 
142. Bourgeois, D. and V. Adam, Reversible photoswitching in fluorescent proteins: a 
mechanistic view. IUBMB Life, 2012. 64(6): p. 482-91. 
143. Schermelleh, L., R. Heintzmann, and H. Leonhardt, A guide to super-resolution 
fluorescence microscopy. J Cell Biol, 2010. 190(2): p. 165-75. 
144. Gustafsson, M.G., Surpassing the lateral resolution limit by a factor of two using 
structured illumination microscopy. J Microsc, 2000. 198(Pt 2): p. 82-7. 
145. Heintzmann, R. and C. Cremer, Laterally modulated excitation microscopy: 
Improvement of resolution by using a diffraction grating. Optical Biopsies and 
Microscopic Techniques Iii, Proceedings Of, 1999. 3568: p. 185-196. 
146. Hell, S.W. and J. Wichmann, Breaking the diffraction resolution limit by 
stimulated emission: stimulated-emission-depletion fluorescence microscopy. Opt 
Lett, 1994. 19(11): p. 780-2. 
147. Klar, T.A., E. Engel, and S.W. Hell, Breaking Abbe's diffraction resolution limit 
in fluorescence microscopy with stimulated emission depletion beams of various 
shapes. Phys Rev E Stat Nonlin Soft Matter Phys, 2001. 64(6 Pt 2): p. 066613. 
148. Dyba, M., S. Jakobs, and S.W. Hell, Immunofluorescence stimulated emission 
depletion microscopy. Nat Biotechnol, 2003. 21(11): p. 1303-4. 
149. Betzig, E., et al., Imaging intracellular fluorescent proteins at nanometer 
resolution. Science, 2006. 313(5793): p. 1642-5. 
150. Rust, M.J., M. Bates, and X. Zhuang, Sub-diffraction-limit imaging by stochastic 
optical reconstruction microscopy (STORM). Nat Methods, 2006. 3(10): p. 793-5. 
151. van de Linde, S., et al., Direct stochastic optical reconstruction microscopy with 
standard fluorescent probes. Nat Protoc, 2011. 6(7): p. 991-1009. 
34 
 
152. Coates, C.G., et al., Optimizing low-light microscopy with back-illuminated 
electron multiplying charge-coupled device: enhanced sensitivity, speed, and 
resolution. J Biomed Opt, 2004. 9(6): p. 1244-52. 
153. Axelrod, D., N.L. Thompson, and T.P. Burghardt, Total internal inflection 
fluorescent microscopy. J Microsc, 1983. 129(Pt 1): p. 19-28. 
154. Lampe, A., et al., Multi-colour direct STORM with red emitting carbocyanines. 
Biol Cell, 2012. 104(4): p. 229-37. 
155. Baker, S.M., R.W. Buckheit, 3rd, and M.M. Falk, Green-to-red photoconvertible 
fluorescent proteins: tracking cell and protein dynamics on standard wide-field 
mercury arc-based microscopes. BMC Cell Biol, 2010. 11: p. 15. 
156. McKinney, S.A., et al., A bright and photostable photoconvertible fluorescent 
protein. Nat Methods, 2009. 6(2): p. 131-3. 
157. Zhang, M., et al., Rational design of true monomeric and bright photoactivatable 
fluorescent proteins. Nat Methods, 2012. 9(7): p. 727-9. 
158. Endesfelder, U., et al., Chemically induced photoswitching of fluorescent probes--
a general concept for super-resolution microscopy. Molecules, 2011. 16(4): p. 
3106-18. 
159. Hammonds, J., et al., The tetherin/BST-2 coiled-coil ectodomain mediates plasma 
membrane microdomain localization and restriction of particle release. J Virol, 
2012. 86(4): p. 2259-72. 
160. Lehmann, M., et al., Quantitative multicolor super-resolution microscopy reveals 
tetherin HIV-1 interaction. PLoS Pathog, 2011. 7(12): p. e1002456. 
161. Gunzenhauser, J., et al., Quantitative super-resolution imaging reveals protein 
stoichiometry and nanoscale morphology of assembling HIV-Gag virions. Nano 
Lett, 2012. 12(9): p. 4705-10. 
162. Malkusch, S., et al., Single-molecule coordinate-based analysis of the morphology 
of HIV-1 assembly sites with near-molecular spatial resolution. Histochem Cell 
Biol, 2013. 139(1): p. 173-9. 
163. Lelek, M., et al., Superresolution imaging of HIV in infected cells with FlAsH-
PALM. Proc Natl Acad Sci U S A, 2012. 109(22): p. 8564-9. 
164. Pereira, C.F., et al., HIV taken by STORM: Super-resolution fluorescence 
microscopy of a viral infection. Virology Journal, 2012. 9. 
165. Itano, M.S., et al., Super-resolution imaging of C-type lectin and influenza 
hemagglutinin nanodomains on plasma membranes using blink microscopy. 
Biophys J, 2012. 102(7): p. 1534-42. 
35 
 
166. Horsington, J., et al., Sub-viral imaging of vaccinia virus using super-resolution 
microscopy. J Virol Methods, 2012. 186(1-2): p. 132-6. 
167. Horsington, J., et al., A36-dependent Actin Filament Nucleation Promotes Release 
of Vaccinia Virus. PLoS Pathog, 2013. 9(3): p. e1003239. 
168. Linnik, O., et al., Unraveling the structure of viral replication complexes at 








Roles played by capsid-dependent induction of membrane curvature 
and Gag-ESCRT interactions in tetherin recruitment  




Tetherin/BST-2 (hereafter tetherin) is an antiviral protein that restricts release of 
diverse enveloped viruses from infected cells through physically tethering virus envelope 
and host plasma membrane. For HIV-1, specific recruitment of tetherin to assembly sites 
has been observed as its colocalization with viral structural protein Gag or its 
accumulation to virus particles. Because of its broad range of targets, we hypothesized 
that tetherin is recruited through conserved features shared among various enveloped 
viruses, such as lipid raft association, membrane curvature, or ESCRT dependence. We 
observed that reduction of cellular cholesterol does not block tetherin anti-HIV-1 
function, excluding an essential role for lipid rafts. In contrast, mutations in the capsid 
domain of Gag, which inhibit induction of membrane curvature, prevented tetherin-Gag 
colocalization detectable by confocal microscopy. Disruption of Gag-ESCRT interactions 
also inhibited tetherin-Gag colocalization, when disruption was accomplished via amino 
acid substitutions in late domain motifs, expression of a dominant negative Tsg101 
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derivative, or siRNA-mediated depletion of Tsg101 or Alix. However, further analyses of 
these conditions by quantitative super-resolution localization microscopy revealed that 
Gag-tetherin coclustering is significantly reduced, but persists at intermediate levels. 
Notably, this residual tetherin recruitment was still sufficient for the full restriction of 
HIV-1 release.  Unlike the late domain mutants, the capsid mutants defective in inducing 
membrane curvature showed little or no coclustering with tetherin in super-resolution 
analyses. These results support a model in which both Gag-induced membrane curvature 
and Gag-ESCRT interactions promote tetherin recruitment, but the recruitment level 
achieved by the former is sufficient for full restriction. 
 
Introduction 
Tetherin (BST-2/CD317/HM1.24/PDCA-1) is an interferon-inducible protein, 
which restricts the release of HIV-1 virions and causes their accumulation at the cell 
surface [1, 2]. Evidence obtained by fluorescence and transmission electron microscopy 
studies show that tetherin accumulates at sites of virus assembly [3-10]. This is consistent 
with a model where tetherin inhibits virus release by directly linking cell and viral 
membranes [3, 5, 6, 9]. This restrictive function is most likely a result of the unique 
topology of tetherin, which contains both an N-terminal transmembrane domain and a 
predicted C-terminal GPI-anchor. The ability of tetherin to form dimers or possibly 
higher-order multimers has also been shown to contribute to its antiviral function [11-15]. 
As with other GPI-anchored proteins, tetherin is thought to reside in lipid rafts, based on 
its resistance to detergent solubilization and cholesterol dependence of this detergent 
resistance [16-18]. Tetherin is able to inhibit a broad range of unrelated enveloped 
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viruses, ruling out a direct interaction with any particular viral protein as a requirement 
for restriction of virus release [19, 20]. 
HIV-1 is able to overcome tetherin-mediated restriction through the action of its 
accessory protein Vpu [1, 2]. Recent studies have determined the nature of the interaction 
between Vpu and tetherin and revealed that Vpu promotes degradation of tetherin and 
sequestration of tetherin away from assembly sites (for reviews, see [19-21]). In contrast, 
the mechanism by which tetherin interacts with assembling viruses remains unknown. 
 The assembly process of HIV-1 likely proceeds in a stepwise fashion [22, 23]. 
Early steps include binding of Gag to the plasma membrane, mediated by the matrix 
(MA) domain [24]. Dimerization of Gag is mediated by the capsid (CA) domain, and 
higher order multimerization is mediated by interactions between the nucleocapsid (NC) 
domain and RNA [23]. Finally, as multimerization progresses, Gag is able to induce 
membrane curvature and, via the late domain (in p6) and NC regions, recruit cellular 
ESCRT machinery to ultimately facilitate scission of host and viral membranes [25]. 
During these steps, assembling Gag also associates with cholesterol-rich lipid rafts as 
well as other membrane microdomains, such as tetraspanin-enriched microdomains [26, 
27]. Similar to dependence on cellular ESCRT machinery for efficient virus release [28, 
29], association with lipid rafts is a common aspect shared among the assembly of many 
enveloped viruses [30]. Because of the association between Gag and lipid rafts, many 
have hypothesized that lipid rafts play an important role in the recruitment of tetherin to 
virus assembly sites [7, 31]. 
To better understand the mechanisms by which tetherin restricts a broad spectrum 
of enveloped viruses, we sought to determine how tetherin is recruited to sites of HIV-1 
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assembly in the absence of Vpu. In this study, we examined the contributions of lipid 
rafts, membrane curvature, and interactions with cellular ESCRT machinery to the 
process of tetherin recruitment to viral assembly sites. 
 
Materials and Methods 
Plasmids and siRNA 
pNL4-3 [32], pNL4-3/Udel (a kind gift from Dr. Klaus Strebel) [33], pNL4-
3/Gag-Venus, pNL4-3/Fyn(10)MA/Gag, and pNL4-3/Fyn(10)fullMA/Gag [34], pNL4-
3/PHPLC1MA/Gag [26], pCMV/Tsg-5’ (a kind gift from Dr. Stanley Cohen) [35], and 
pCDNA3.1/HIV-Tat101 (a kind gift from Dr. David Markovitz) [36], were described 
previously. pCMV/Rev, a kind gift from Dr. Eric Freed, was originally obtained from Dr. 
S. Venkatesan [37]. Udel versions of previously described pNL4-3-based plasmids were 
created by replacing the SalI/BamHI fragment of pNL4-3 with the corresponding region 
of pNL4-3/Udel, which does not express Vpu [33]. A plasmid encoding the full length 
cDNA of human BST-2/Tetherin under the control of a CMV promoter, pCMV6XL-5 
hBST-2, was obtained from Origene (Rockville, MD). Plasmids used to make 
pseudotyped virus stocks, pCMVNLGagPolRRE [38] and pHCMV-G (a kind gift from 
Dr. Jane Burns) [39], were described previously. Capsid mutations previously shown to 
disrupt membrane curvature and efficient particle formation, P99A [40] and EE75,76AA 




Venus/Udel (p6 residues 7-10 were changed from PTAP to LIRL [42]), pNL4-3/CCY
-
/Gag-Venus/Udel (bearing NC C28S, NC C49S, and p6 Y36S mutations [43]), and 
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pNL4-3/Y36S/Gag-Venus/Udel (p6 Y36S mutation [44]) were generated by standard 
PCR mutagenesis techniques. The gene encoding the photo-switchable fluorescent 
protein mEos2 was obtained from the pRSETa mEos2 plasmid from Addgene 
(Cambridge, MA). The bright, monomeric version of the Eos fluorescent protein, 
mEos3.2, was generated by PCR mutagenesis of the parental mEos2 protein (bearing 
I102N, H158E, and Y189A mutations ) as described [45]. pNL4-3/Gag-mEos3.2/Udel 
and its derivatives were constructed by replacing the Venus coding sequence with 
mEos3.2. The CA/NC mutant used in this study, pNL4-3/20LK/WM/14A1G/Gag-
mEos3.2/Udel, bears the MA mutation 20LK [46] to facilitate efficient membrane 
binding in the absence of normal multimerization, which are disrupted by capsid C-
terminal mutations W184A and M185A (WM) and mutations of the 15 basic amino acids 
of the NC domain to alanine or glycine (14A1G) [47]. siRNA sequences directed against 
Tsg101 (CCUCCAGUCUUCUCUCGUC) and Alix (GAAGGAUGCUUUCGAUAAA) 
were described previously [48, 49]. A control siRNA, which does not target any known 
human mRNA sequences (UUCUCCGAACGUGUCACGU), was also used [50]. 
Double-stranded RNA oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, IA). 
 
Antibodies 
Anti-BST-2/tetherin polyclonal rabbit serum, generated by Dr. Klaus Strebel [51], 
and anti-HIV-Ig polyclonal human serum were obtained from the NIH AIDS Research & 
Reference Reagent Program (Germantown, MD). Monoclonal mouse antibodies against 
CD46, CD55, CD59, and Tsg101 were obtained from BD Biosciences (San Diego, CA). 
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Polyclonal rabbit anti-GFP was obtained from Clontech (Mountain View, CA). Mouse 
polyclonal anti-PDC6I (Alix) was obtained from Abcam (Cambridge, MA). Monoclonal 
mouse anti--tubulin was obtained from Sigma (St. Louis, MO). Species- and/or isotype-
specific Alexa Fluor 488-, 594-, and 647-conjugated secondary antibodies were obtained 
from Invitrogen (Carlsbad, CA). Alexa Fluor 647-conjugated monoclonal anti-human 
CD317 (tetherin) was obtained from BioLegend (San Diego, CA). 
 
Cells 
HeLa cells were maintained in DMEM supplemented with 5% FBS. HT-1080 
cells (ATCC #CCL-121) were maintained in EMEM supplemented with 10% FBS. For 
virus release assays, cells were plated at a density of 5.6x10
5
 per well in 6-well culture 
plates and incubated overnight. Cells were then transfected with 2 g of pNL4-3-based 
plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. In HT-1080 cells, 2 g pNL4-3-based plasmids were used 
with or without 50 ng pCMV6XL-5 hBST2. Transfection for microscopy was performed 
as previously described [26]. For T cell experiments, A3.01 and a derivative cell line, P2 
[52], were maintained in RPMI-1640 with 10% FBS. 
 
Cholesterol Depletion and Virus Release Assays 
Cholesterol depletion [38] and virus release assays [34] were performed as 
previously described. VLP release assays of PR
-
 Gag, Gag-Venus, and Gag-mEos3.2 
were performed in a similar manner with the exception that cell lysates were subjected to 
boiling with a low concentration of SDS prior to immunoprecipitation and VLP lysates 
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were loaded directly, without immunoprecipitation, to minimize epitope masking 
resulting from the lack of functional protease in these molecular clones [53]. 
 
Antibody Copatching Assay, Confocal Microscopy, and Image Analysis 
HeLa cells were plated and transfected as described above followed by 16-hour 
incubation at 37°C. For antibody copatching assay, cells were stained by primary 
antibodies at 1:100 in DMEM-5% FBS for 10 minutes at room temperature, washed 3 
times with PBS, and stained by secondary antibodies at 1:200 in DMEM-5% FBS for 10 
minutes at room temperature. Cells were then washed 3 times and fixed with 4% PFA in 
PBS for 30 minutes at room temperature. For standard immunofluoresence microscopy, 
cells were fixed with 4% PFA in PBS for 30 minutes at room temperature and stained by 
primary and secondary antibodies for 1 hour each. Samples were mounted in 
Fluoromount-G (Southern Biotech, Birmingham, AL) and imaged on a Leica SP5X 
microscope (Leica, Wetzlar, Germany). Images were acquired with a 100X PL APO 
objective (NA=1.40) with 5X scanning zoom at a resolution of 1024x1024 (30 nm per 
pixel). Excitation was done with 488 nm, 514 nm, and 590 nm laser lines. Acquisition 
bandwidths were 500-550 nm, 525-575 nm, and 600-650 nm, respectively.  
To calculate the degree of colocalization between markers, at least 10 regions of 
interest, each from different fields, were analyzed per condition. Regions of interest were 
randomly selected from cells where two proteins of interest were present. For Gag-
tetherin colocalization measurements, we excluded cells that do not show distinct Gag 
puncta from analyses. Pearson’s correlation coefficient was calculated using ImageJ 
1.43u (NIH, http://rsb.info.nih.gov/ij/) with the JACoP plugin [54]. For confocal images 
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of tetherin, a smoothing filter was applied in ImageJ after images were analyzed to 
remove excess background signal. This filter sets the intensity value at each pixel equal 
to the average of its nearest neighbors in at 3x3 pixel square area. 
 
T Cell Infection and Microscopy 
Generation of pseudotyped virus stocks, infection of A3.01 and P2 T cells, and 
immunofluorescence microscopy were performed as described previously [52]. Images 
were analyzed as described above for HeLa cells, with the exception that a median filter 
was applied in ImageJ prior to analysis to remove out of focus signals from 
epifluorecence images. For virus release assay, 4x10
5
 P2 T cells were spinoculated with 
VSV-G-pseudotyped virus in the presence of 0.8 g polybrene and incubated for 2 days 
prior to metabolic labeling. 
 
Transmission Electron Microscopy Analysis of Gag-Venus Mutants 
HeLa cells were plated and transfected as described above. Cells were fixed 16 
hours post-transfection with 2% glutaraldehyde in PBS. Cells were analyzed on a Hitachi 
H7600 transmission electron microscope as previously described [55].  
 
Super-Resolution Localization Microscopy and Cross-Correlation Analysis 
HeLa cells were plated and transfected as described above. Cells were fixed at 16 
hours post-transfection in 4% PFA with 0.1% glutaraldehyde for 10 minutes at room 
temperature. Cells were then stained by Alexa Fluor 647-conjugated monoclonal anti-
tetherin antibody for 2 hours at room temperature. Cells were washed extensively with 
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PBS and placed in imaging buffer composed of 50mM Tris-HCl pH 9.0, 10mM NaCl, 
1% -ME, 10% glucose, and an enzymatic oxygen scavenging system as described 
previously [56]. Samples were imaged in total internal reflection using an inverted IX81-
ZDC microscope with a cellTIRF module (Olympus America, Center Valley, PA) and 
100X UAPO TIRF objective (NA=1.49). Images were acquired on an EMCCD camera 
(iXon-897, Andor, Belfast, Ireland). Red and far red emissions were separated onto two 
halves of the EMCCD camera using a DV2 dualview imaging system equipped with a 
650nm long pass dichroic and emission filters (Photometrics, Tucson, AZ).  Alexa-647 
fluorophores were activated and imaged with 640nm laser excitation (CUBE 640-75FP, 
Coherent, Santa Clara, CA), while Gag-mEos3.2 fluorophores were activated at 405nm 
(CUBE 405-50FP, Coherent, Santa Clara, CA) and imaged using laser excitation at 
561nm (Sapphire 561-150 CW, Coherent, Santa Clara, CA).  In both cases, laser 
intensities were adjusted such that single fluorophores could be distinguished in 
individual images.  Super-resolution images were reconstructed from 7500 individual 
diffraction limited images according to previously described methods [56] implemented 
in custom software written in Matlab (Mathworks, Natick, MA).  Briefly, single molecule 
peaks were identified and fit to a two dimensional Gaussian shape. The ensemble of 
peaks was then culled to remove outliers in brightness, size, aspect ratio, and localization 
error. The culling algorithm is designed to remove likely contributions from signals that 
do not originate from single activated fluorophores so that they do not contribute to the 
final image. Therefore, in the final images, the smallest/dimmest puncta, which do not 
contain more-than-one single activation events, are likely to represent single molecules. 
Culled events are not correlated in space. Fiduciary markers were used to transform 
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Alexa647 and mEos3.2 images following previously published methods [57], and stage 
drift was corrected by aligning single color super-resolution images generated from 
signals acquired every 100-500 frames by localizing the maxima of cross-correlation 
functions. Super-resolution images were reconstructed by incrementing the intensity of 
pixels at positions corresponding to localized single molecules after correcting for stage 
drift.  Image resolution is estimated by comparing the auto-correlation of images 
reconstructed from all identified single molecule centers to those of images reconstructed 
from data grouped to account for localized single molecules that remain activated in 
sequential frames as described previously [58].  Cross-correlation functions,     , as a 
function of radius, r, for cells were evaluated from ungrouped reconstructed images, were 
computed using fast Fourier transforms as described previously [59], and were 
normalized to 1 at large radius.  
To facilitate the comparison of the levels of cross-correlations between 
conditions, we report the integrated intensity under cross-correlation curves, out to a 
radius of 1µm.  To accomplish this, curves tabulated from individual cells were first fit to 
the sum of Gaussian and exponential functions in order to average noise at large radii.  
Best fit curves were then integrated according to                 
   
   , where    
is the distance between adjacent points in the tabulated correlation functions (25nm).  The 
number of Gag (tetherin) proteins correlated with the average tetherin (Gag) protein out 
to a radius of 1µm is given by     , where   is the average surface density of Gag 
(tetherin).  The values presented in Figures 2.5F and 2.7D (integrated cross-correlation) 
are integrated intensity ( ) divided by integrated area (      
   
   ).  The resulting value 
is equal to the increased surface density of Gag (tetherin) coclustered with tetherin (Gag).  
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The Pearson’s correlation coefficient used to quantify colocalization in confocal 
microscopy images and the integrated cross-correlation analysis method used for super-
resolution localization microscopy images are not directly comparable. The Pearson’s 
coefficient is the covariance (cross-correlation at r=0) between the two images divided by 
the variance (square root of the autocorrelation function at r=0) of each individual image 
[59], whereas the integrated cross-correlation values are for r=0-1 µm and not affected by 
the auto-correlation functions.  Unfortunately, it is not possible to evaluate reliable 
Pearson’s coefficients from super-resolution images due to over-counting artifacts in 
auto-correlation functions (details described in [58]). 
 
siRNA Knockdowns 
HeLa cells were plated at a density of 10
5
 cells per well in 24-well culture plates 
(Corning, Fairport, NY) and incubated overnight. Cells were then transfected with 20 pM 
siRNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. After 24 hours, cells were trypsinized, transferred into Lab-
Tek 8-well chamber slides (Thermo Fisher, Waltham, MA; for confocal microscopy), 
Lab-Tek 4-well chamber coverslips (for super-resolution microscopy), or 6-well culture 
plates (Corning, Fairport, NY; for western blot analysis and virus release assays), and 
further incubated for 24 hours. For microscopy, cells were then transfected with 0.6 g 
pNL4-3-based plasmids and incubated for an additional 16 hours prior to fixation and 
staining as described above for confocal or super-resolution localization microscopy (a 
total of 64 hours after siRNA transfection). For western blot analysis, cells were lysed at 
64 hours after siRNA transfection and lysates were subjected to SDS-PAGE and 
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immunoblotting. For virus release assays, cells were transfected with siRNA as described 
above, transfected with pNL4-3-based plasmids at 48 hours after siRNA transfection and 




Tetherin does not copatch significantly with lipid raft markers in HeLa cells 
Given the known involvement of lipid rafts in the assembly of many tetherin-
susceptible enveloped viruses, it is possible that lipid rafts may direct tetherin to sites of 
HIV-1 assembly. To determine whether tetherin is associated with lipid rafts, we used an 
antibody copatching assay to examine the distribution of endogenous tetherin and lipid 
raft markers on the surface of HeLa cells. By the same assay, Gag has been previously 
shown to strongly associate with lipid raft markers in HeLa cells [26]. In the present 
study, we observed substantial copatching of tetherin with Gag-YFP but not with a non-
raft marker CD46 (Figure 2.1). We also observed a moderate level of copatching between 
two lipid raft markers NFP-GPI (a GPI-anchored non-fluorescent GFP variant) and CD59 
and between NFP-HATM (a fusion between the transmembrane domain of influenza HA 
and NFP) and CD55 in the absence of Gag (Figure 2.1). However, no significant 
copatching was observed between tetherin and four different lipid raft markers CD55, 
CD59, NFP-GPI, and NFP-HATM in the absence of Gag (Figure 2.1). These results 
suggest that, although tetherin can be recovered from detergent resistant membrane 
fractions, it does not appear to have a strong affinity for lipid rafts detected in this 






Figure 2.1. Tetherin copatches with Gag-YFP but not with CD46 or lipid raft markers.  
HeLa cells were treated with primary antibodies against indicated proteins expressed on the cell surface for 
10 minutes, followed by treatment with species- and/or isotype-specific fluorescent secondary antibodies 
for 10 minutes, and fixation with 4% PFA for 30 minutes. Cells expressing Gag-YFP were treated with 
antibodies to patch tetherin alone prior to fixation. (A) Representative images of the dorsal surface of cells 
are shown. (B) Pearson’s correlation coefficients were calculated for fluorescence intensities of green and 
red signals at each pixel. Data shown are from 10 regions of interest, each from different cells, from one 
representative experiment out of two performed, displayed as mean Pearson’s correlation (R) values ± 




Tetherin antiviral function is insensitive to cholesterol depletion 
While a recent report showed that treatment of cells by anti-tetherin antibody does 
not apparently alter cell-surface distribution of tetherin [60], we cannot rule out the 
possibility that antibody treatment may alter the native microdomain partitioning of 
tetherin. To assess tetherin-raft association and its significance by an alternative 
approach, we sought to determine whether lipid rafts play a role in tetherin antiviral 
function. To this end, we depleted cellular cholesterol that is essential for lipid-raft 
integrity by methyl--cyclodextrin (MCD) and examined the effect of this treatment on 
tetherin-mediated inhibition of virus release. We found that under both mild (30 minutes 
with 5 mM MCD) and more stringent (30 minutes with 10 mM MCD) cholesterol-
depleting conditions, tetherin remains a potent inhibitor of WT Gag release in HeLa cells 
as assessed by Vpu dependence of virus release (Figure 2.2 A-C). While association of 
Vpu with lipid rafts is debated [17, 61, 62], such association could be a confounding 
factor in the experiments using HeLa cells. To directly examine the effect of tetherin, we 
used HT-1080 cells that do not express endogenous tetherin.  We observed that in these 
cells, exogenously expressed tetherin inhibits virus release regardless of cholesterol 
depletion treatments (Figure 2.2 D-F). However, cholesterol depletion is also known to 
significantly inhibit membrane binding and release of WT Gag [38, 63]. To separate the 
effects of cholesterol depletion on virus particle production and tetherin function, we 
conducted similar experiments using Fyn(10)fullMA Gag, which contains the first 10 
amino acids of Fyn kinase at the N-terminus of Gag. Virus particle production of this Gag 
derivative is less sensitive to cholesterol depletion than WT Gag [63]. We found that 






Figure 2.2. Tetherin antiviral function is insensitive to cholesterol depletion.  
Virus release assays were performed in HeLa cells transfected with HIV-1 molecular clones that express 
Vpu or not (A, B, and C) and in HT-1080 cells transfected with Vpu-deficient molecular clones with or 
without exogenously expressed tetherin (D, E, and F). These molecular clones encode either WT Gag or 
Fyn(10)fullMA Gag. Cells were cultured in Met/Cys-deficient media containing FBS or cholesterol-
depleted serum (CDS) and 5 mM or 10 mM MCD prior to metabolic labeling with [
35
S] Met/Cys for two 
hours. Virus release efficiency was determined as (virus-associated Gag)/(total Gag) and normalized to 
virus release efficiency in cells cultured in the medium containing FBS under Vpu (+) or tetherin (-) 
conditions. Data shown are from three independent experiments displayed as mean ±1 standard deviation. 




conditions in HeLa and HT-1080 cells (Figure 2.2). These results indicate that tetherin 
antiviral function is insensitive to cholesterol depletion. Altogether, cholesterol depletion 
and microscopy data suggest that lipid rafts do not play an essential role in tetherin 
association with assembling Gag and tetherin-mediated inhibition of HIV-1 release. 
 
CA mutations that impair induction of membrane curvature block tetherin 
recruitment 
 Next, we focused on whether membrane curvature and recruitment of cellular 
ESCRT machinery, which are common events among assembly of many unrelated 
enveloped viruses, are required for tetherin recruitment to assembly sites. To test the role 
of membrane curvature in tetherin recruitment, we utilized two different Gag mutants that 
are able to bind the plasma membrane and multimerize but are unable to induce the 
typical membrane curvature seen with WT Gag [26]. These two mutations, CA P99A 
[40] and CA EE75,76AA [41], were introduced into an HIV-1 molecular clone encoding 
a Gag-YFP fusion. To validate whether these Gag mutations have the expected impacts 
on membrane curvature in the context of Gag-YFP fusions, we first performed 
transmission electron microscopy analyses and VLP release assays using HeLa cells 
transfected with Vpu
+
 molecular clones expressing WT, P99A, and EE75,76AA Gag-
YFP (Figure 2.3A and B). We found that consistent with the membrane curvature defect 
observed for non-YFP tagged versions (unpublished data) [26, 41], both P99A and 
EE75,76AA produced electron-dense patches beneath the plasma membrane and  were 
reduced in VLP production, although the defect was much more severe with the 





Figure 2.3. Membrane curvature and Tsg101 binding correlate with tetherin recruitment in HeLa 
cells.  
(A) HeLa cells expressing Vpu
+
 molecular clones encoding indicated mutants of Gag-YFP were analyzed 
by transmission electron microscopy. Arrows indicate electron-dense patches that are likely to represent 
membrane-associated Gag-YFP multimers. Scale bar = 100 nm. (B) VLP release assay of Vpu
+
 Gag-YFP 
constructs was performed for indicated Gag-YFP constructs in HeLa cells as in Figure 2.2. Representative 
autoradiogram is shown along with quantitation of VLP release efficiency. Data shown are from 2 
independent experiments displayed as mean VLP release efficiency. (C and D) HeLa cells expressing 
molecular clones encoding indicated Gag-YFP constructs and lacking the vpu gene were fixed at 16 hours 
post-transfection with 4% PFA for 30 minutes and immunostained for endogenous tetherin expressed on 
the cell surface. (C) Representative images of the dorsal surface of cells are shown. Scale bar = 5.0 m. (D) 
Degree of colocalization between Gag-YFP and tetherin was calculated in the same manner as in Figure 
2.1. Results are shown for one of two independent experiments and displayed as mean R ± SEM. *, p < 






assembly, budding, and release of the spherical VLPs that are still observed to occur in an 
apparently WT-like manner albeit at the low levels (unpublished data) [26]. We next 
introduced the same CA mutations into a molecular clone lacking Vpu expression (pNL4-
3/Gag-YFP/Udel) and examined the distributions of tetherin and Gag in the absence of 
Vpu-mediated down-modulation of tetherin by immunostaining.  Cells were fixed prior to 
immunostaining to prevent antibody-driven copatching. Both CA mutants show 
significantly lower colocalization with tetherin than WT Gag-YFP (Figure 2.3C and D). 
These results identify the CA amino acid residues substituted in these mutants as 
molecular determinants in tetherin recruitment to HIV-1 assembly sites and suggest a 
possible role for membrane curvature in tetherin recruitment. Alternatively, these mutants 
may be defective at a stage of assembly prior to when tetherin recruitment occurs. 
 
The Interaction between Gag and Tsg101 enhances tetherin recruitment in HeLa 
cells 
Following the induction of membrane curvature and the formation of viral buds, 
ESCRT-mediated scission of viral and host membranes occurs. An ESCRT-I protein 
Tsg101, as well as an ESCRT-related protein Alix (AIP1/PDCD6IP), serve as an 
interface of the ESCRT machinery with Gag and facilitate efficient virus release [64-68]. 
To determine whether the ESCRT complex contributes to tetherin recruitment, we 
examined the impact of a dominant negative form of Tsg101, called Tsg-5’, on tetherin-
Gag colocalization. Tsg-5’ corresponds to the N-terminal half of Tsg101 that binds HIV-
1 p6 [64, 69] and lacks the C-terminal half of the protein responsible for recruiting other 
ESCRT proteins [68, 70]. Expression of this protein has been shown to inhibit virus 
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release of HIV-1 [66]. We observed a significant reduction in tetherin-Gag colocalization 
when Tsg-5’ was expressed (Figure 2.3C and D), suggesting that the interaction between 
ESCRT and Gag is responsible for specific recruitment of tetherin.  
Tsg101 binds to Pro-(Thr/Ser)-Ala-Pro (PT/SAP) motifs, including the PTAP 
motif in Gag p6 domain [64, 69, 71]. To abrogate this binding, we exchanged the PTAP 
motif sequence of the p6 domain for Leu-Ile-Arg-Leu, referred to as PTAP
-
 Gag-YFP. 
This change is known to inhibit virus release [42, 72]. Binding of Alix occurs through 
two different regions of Gag. The first known motif, LYPxnL, is within p6, and its 
binding to Alix can be disrupted by the p6 Y36S mutation [43, 44]. The second binding 
site lies within the NC domain [43, 73], and its interaction with Alix can be disrupted by 
the double mutant NC C28S/C49S [43]. To remove both Alix binding sites from Gag, we 
constructed a triple mutant (NC C28S/C49S and p6 Y36S), referred to as CCY
-
 Gag-




 mutants exhibited a budding-
arrested phenotype characteristic of late domain/ESCRT disruption and failed to release 
VLPs (Figure 2.3A and B). In the case of CCY
-
 mutant, the failure of VLP release may 
also be partially due to an additional defect in Gag assembly caused by mutations in the 
zinc fingers of the NC domain [74, 75].  When expressed in HeLa cells, in the vpu-
negative context, PTAP
-
 Gag-YFP showed significantly less colocalization with tetherin, 
while CCY
-
 Gag-YFP showed levels of colocalization which were not significantly less 
than WT Gag-YFP (Figure 2.3C and D). We also observed similar levels of 
colocalization with the single mutant p6 Y36S (data not shown). These results suggest 
that in HeLa cells, the interaction between Tsg101 and the PTAP motif of Gag p6 domain 
promotes recruitment of tetherin. 
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The interaction between Gag and ESCRT enhances tetherin recruitment in T cells 
 To test whether members of the ESCRT complex participate in tetherin 
recruitment in T cells, which are a natural host cell type for HIV-1 in vivo, we infected 
A3.01 T cells with stocks of VSV-G-pseudotyped HIV-1 encoding WT Gag-YFP, PTAP
-
 
Gag-YFP and Y36S Gag-YFP and lacking vpu. After 48 hours, cells were fixed and 
immunostained for surface tetherin. In contrast to the observation that only the Tsg101 
binding site of Gag is required for tetherin recruitment in HeLa cells, both PTAP
-
 and 
Y36S mutations decreased colocalization of Gag-YFP with tetherin in A3.01 T cells 
(Figure 2.4). However, we noted that the impact of the Y36S change was modest (Figure 
2.4). Similar results were also observed in primary human CD4
+
 T cells (data not shown). 
These data show that both Tsg101 and Alix binding sites within Gag p6 domain enhance 
tetherin recruitment to Gag assembly sites in T cells. In A3.01 cells, the CCY
-
 triple 
mutant failed to form distinct puncta at the plasma membrane unlike in HeLa cells and, 
therefore, was not assessed for tetherin recruitment (data not shown). 
 
siRNA knockdown of Tsg101 or Alix decreases tetherin recruitment in HeLa cells 
 To further assess the importance of Tsg101 and Alix in tetherin recruitment, we 
analyzed the effect of siRNA-mediated depletion of endogenous Tsg101 and Alix 
proteins in HeLa cells (Figure 2.5). Using previously reported siRNA duplex sequences 
[48, 49], substantial depletion was achieved for both proteins (Figure 2.5A). We found 
that depletion of either Tsg101 or Alix caused a marked decrease in tetherin 
colocalization with Gag-YFP. In contrast, significant colocalization was observed in cells 





Figure 2.4. Both Tsg101- and Alix-binding sites in Gag are required for maximal tetherin 
recruitment in T cells.  
A3.01 T Cells were infected with VSV-G-pseudotyped viruses expressing indicated Gag-YFP derivatives 
and lacking the vpu gene. After 48 hours cells were fixed with 4% PFA for 30 minutes and immunostained 
for endogenous tetherin expressed on the cell surface. (A) Representative images of the dorsal surface of 
cells are shown. Scale bar = 5.0 m. (B) Quantitation of colocalization was performed as in Figure 2.1 after 
application of median filter. Results are shown for one of two independent experiments and displayed as 




These data indicate that both Tsg101 and Alix enhance tetherin recruitment to 
assembling Gag-YFP in HeLa cells. In addition to the observed loss of colocalization 
between tetherin and Gag after Tsg101 or Alix depletion, it is of note that both conditions 
also appear to show a more diffuse staining pattern for tetherin (Figure 2.5B). This could 
either indicate that recruitment of tetherin to assembly sites results in a more punctate 
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staining pattern of tetherin, as seen with WT Gag-YFP, or potentially that depletion of 
these proteins may alter the native distribution of tetherin at the plasma membrane, or 
both.  
To analyze the contribution of ESCRT-Gag interactions to tetherin recruitment at 
the level of single virus particles, we utilized super-resolution localization microscopy. 
To achieve high-resolution information by this technique, proteins of interest are either 
tagged with photo-switchable or photo-activatable fluorescent proteins or immunolabeled 
by certain organic fluorophores, which are capable of reversible photo-switching in a 
reducing buffer [56, 76]. For our experiments, we fused Gag to the recently developed, 
green-to-red photo-switchable fluorescent protein mEos3.2 [45]. Unlike its parent protein 
mEos2 [77], which is able to form dimers and tetramers, mEos3.2 is truly monomeric and 
presumably does not affect the multimerization state of fusion proteins. mEos3.2 has also 
been shown to exhibit superior spectral qualities and is capable of reversible photo-
switching in reducing buffer, making it an ideal fusion protein for super-resolution 
localization microscopy [45]. For our experiments, we depleted Tsg101 and Alix in HeLa 
cell by siRNA as in previous experiments. Cells were then transfected with a molecular 
clone expressing a Gag-mEos3.2 fusion protein and lacking vpu. Cells were then fixed, 
labeled with an AlexaFluor-647-conjugated monoclonal antibody directed to tetherin, and 
placed in a reducing buffer [78] before imaging by TIRF microscopy [56]. Given the high 
resolution that was achieved by this technique (25 nm for Gag-mEos3.2 and 15 nm for 
tetherin), we chose to quantify images using cross-correlation analysis, which reflects the 
degree of coclustering of two proteins as a function of distance, rather than Pearson’s 






Figure 2.5. siRNA-mediated depletion of Tsg101 or Alix decreases tetherin recruitment in HeLa cells.  
(A) Western blotting analysis of Tsg101 and Alix in cells transfected with indicated siRNA and lysed at 64 
hours post-transfection. Alpha-tubulin is shown as a loading control. (B and C) HeLa cells were transfected 
sequentially with the indicated siRNA and a molecular clone encoding Gag-YFP without Vpu. At 64 hours 
post-transfection with siRNA (16 hours post-transfection with Gag-YFP expression plasmids), cells were 
fixed by 4% PFA for 30 minutes and immunostained for endogenous tetherin. (B) Representative images of 
the dorsal surface of cells are shown. Scale bar = 5.0 m. (C) Degree of colocalization was calculated in the 
same manner as in Figure 2.1. The result is shown for one of two independent experiments and displayed as 
mean R ± SEM. *, p < 0.01. (D) HeLa cells were transfected with indicated siRNA, followed by 
transfection with a Vpu-deficient molecular clone expressing Gag-mEos3.2. Cells were then fixed, stained 
with AlexaFluor-647 anti-tetherin antibody, and imaged by TIRF. Super-resolution images were 
reconstructed as described in Materials and Methods. Representative images are shown. Magnified images 
for boxed areas in the left panels are shown on the right. Scale bars are 2 m for the left panels and 500 nm 
for the right panels. (E) Images of five cells per condition were acquired in each of two independent 
experiments (total 10 cells) and used for measurement of Gag-tetherin cross-correlation. Cross-correlation 
values are shown as mean ± SEM. Dashed line indicates random distribution (cross correlation =1). (F) 
Integrated cross-correlation was calculated as described in Materials and Methods and is shown as mean 
integrated cross-correlation ± SEM. *, p < 0.05. 
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pixel. To determine the degree of coclustering between tetherin and Gag-mEos3.2, we 
employed a statistical cross-correlation analysis, which measures the increased 
probability of finding a detected tetherin protein at a given distance from a detected Gag 
protein, or vice versa [58]. A normalized cross-correlation of 1 is observed when the 
distribution of detected molecules in one color channel is independent of the distribution 
of detected molecules in the other color channel. In contrast, a correlation greater than 1 
is observed when signals from the two channels are not independent and show 
coclustering. When we quantified images of WT Gag-mEos3.2 and tetherin for cross 
correlation up to radii of 1 µm, we observed a high degree of cross correlation 
particularly within 100 nm when cells were treated with a non-target siRNA (Figure 
2.5D–E). In contrast, when Tsg101 or Alix were depleted by siRNA, we observed 
intermediate levels of tetherin-Gag coclustering at the same range of radii (Figure 2.5D–
E). To facilitate the comparison between conditions, we used the integrated cross-
correlation between r=0 and r=1000 nm (see Materials and Methods) (Figure 2.5F). By 
this method, both Tsg101- and Alix-depleted cells showed significantly less coclustering 
between tetherin and Gag-mEos3.2 than cells treated with control siRNA. The reduction 
in Gag-tetherin colocalization caused by the same siRNA treatment (Figure 2.5C) appears 
more severe than that in coclustering (Figure 2.5F).  This is likely due to differences 
between the methods used to quantify colocalization and coclustering in the two 
experiments. In particular, diffuse tetherin signals observed in Tsg101- or Alix-depleted 
cells, which reduce the contrast in tetherin localization inside versus outside Gag patches, 
are likely to contribute to reduction of Pearson’s correlation coefficients, whereas they 
would not necessarily affect cross-correlations. Regardless, both confocal and super- 
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resolution microscopy data indicate that both Tsg101 and Alix promote tetherin 
recruitment to HIV-1 assembly sites and yet that intermediate levels of recruitment still 
occur in Tsg101- or Alix-depleted HeLa cells. 
  
Intermediate levels of tetherin recruitment are sufficient for virus-release inhibition 
To determine whether the maximal colocalization/coclustering between tetherin 
and Gag, which was observed to be ESCRT-dependent (Figure 2.5), is required for 
tetherin function, we sought to assess the ability of tetherin to inhibit release of WT HIV-
1 upon depletion of Alix. Previous studies showed that unlike depletion of other ESCRT 
proteins such as Tsg101, depletion of Alix has little effect on ESCRT-mediated release of 
HIV-1[79, 80].  Therefore, the effect of Alix depletion on tetherin function can be 
examined specifically without confounding effect on particle scission. We treated HeLa 
cells with siRNAs in the same transfection procedure as in Figure 2.5 and measured 




 molecular clones in these HeLa cells. We 
found that virus release of Vpu
-
 HIV-1 was inhibited compared with that of Vpu
+
 HIV-1 
in Alix-depleted HeLa cells as potently as, or even slightly more potently than, in HeLa 
cells treated with control siRNA (~25 fold versus ~21 fold; Figure 2.6A-C). These results 
suggest that while Alix is required for a maximal colocalization and coclustering between 
tetherin and Gag, this high level of clustering is not necessary for the full antiviral 
activity of tetherin.  
Virus release enhancement by Vpu is well documented for a T cell line A3.01 
[33], which has been shown to express a detectable level of tetherin on the cell surface [6, 






Figure 2.6. Disruption of Gag-ESCRT interactions does not affect tetherin function. 
(A-C) HeLa cells were transfected with either non-target or Alix-directed siRNA. At 48 hours after 




 HIV-1 molecular clones. Cells were 
incubated for 16 hours (64 hours post-transfection with siRNA), followed by metabolic labeling and 
immunoprecipitation with HIV-Ig as in Figure 2.1. Representative autoradiograms of cell- and virus-
associated proteins are shown for experiments using HeLa cells (A). (B) The cellular amounts of Alix and 
-tubulin in cells treated as in panel A were examined by immunoblotting.  Note that the same transfection 
procedure was used to deplete Tsg101 and Alix in Figure 2.5. (C) Quantitation of virus release efficiency 
from 3 independent experiments is shown as mean ±1 standard deviation. (D and E) P2 T cells were 
spinoculated with the indicated viruses with or without Vpu and incubated for 48 hours, followed by 
metabolic labeling and immunoprecipitation.  One of three autoradiograms is shown (D). (E) Quantitation 






recruitment appear to play a less critical role in virus release in T cells including an 
A3.01 cell clone [72]. Taking advantage of this difference, we sought to assess the 
contribution of both Tsg101 and Alix interactions in tetherin function in an A3.01-
derived cell clone, P2. For these experiments P2 cells were spinoculated with VSV-G-
pseudotyped viruses expressing either WT, PTAP
-
, or Y36S Gag proteins either with or 
without vpu. In these experiments, the p6 mutants produced virus particles at a markedly 
impaired but still detectable level in the presence of Vpu (Figure 2.6D and E). Notably, 
deletion of Vpu reduced virus release to the similar extent for WT and p6 mutant Gag 
proteins. In other words, we did not observe any reversal of virus release restriction when 
either the Tsg101- or primary Alix-binding sites were mutated in Gag. These results 
corroborate the results obtained with siRNA experiments performed using HeLa cells 
(Figure 2.6A-C) and suggest that Gag-ESCRT interactions are not required for the 
antiviral activity of tetherin.  
Altogether, these results indicate that although Gag-ESCRT interactions cause a 
detectable and significant increase in tetherin recruitment, the intermediate levels of 
tetherin recruitment observed when Tsg101 or Alix are depleted are sufficient for full 
inhibition of virus particle release.  
 
Intermediate levels of tetherin recruitment, which are sufficient for virus release 
inhibition, are dependent on intact CA sequences required for Gag-induced 
membrane curvature 
 To identify molecular determinants for the intermediate levels of tetherin 
recruitment observed in previous experiments, which is sufficient for full inhibition of 
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virus release, we analyzed coclustering between endogenous tetherin and several Gag 
mutants in HeLa cells by super-resolution localization microscopy. As in Figure 2.3, we 
utilized two CA mutants that form electron-dense Gag patches at the plasma membrane 
but fail to induce membrane curvature efficiently (P99A Gag-mEos3.2 and EE75,76AA 
Gag-mEos3.2). We also examined the effect of Tsg5’ expression and mutations of 
Tsg101- and Alix-binding motifs in Gag (PTAP
-
 Gag-mEos3.2 and CCY
-
 Gag-mEos3.2) 
on tetherin-Gag coclustering. Virus release assays showed that replacement of YFP with 
mEos3.2 does not grossly affect efficiencies of VLP release by Gag mutants except that 
the virus release defect of P99A Gag was more severe in the mEos3.2 context than in the 
YFP context (data not shown). To establish a baseline for analysis, we also used a Gag-
derivative that contains mutations at both CA dimer interface and NC basic residues 
(20LK/WM/14A1G/Gag-mEos3.2; hereafter CA/NC Gag-mEos3.2). Due to these 
mutations, this Gag derivative was expected to be highly defective in multimerization and 
therefore was expected to not cocluster with tetherin. As expected, by standard TIRF 
microscopy, which is inherently diffraction-limited, CA/NC Gag displays a largely 
uniform, diffuse membrane-lining phenotype with some patches (Figure 2.7A) that may 
represent membrane topology [81]. Reconstructed super-resolution images show various 
sizes of small puncta of CA/NC Gag-mEos3.2 at the plasma membrane, which likely 
represent single molecules and perhaps small clusters of Gag molecules (Figure 2.7B). 
WT and other mutants appeared to show more of larger puncta (Figure 2.7B; data not 
sown). After analyzing the Gag mutants described above in the same manner as in Figure 
2.5, we found that there are three distinct categories of tetherin-Gag coclustering (Figure 







Figure 2.7. Both membrane curvature and Gag-ESCRT interactions enhance tetherin recruitment in 
HeLa cells. 
 (A) Cells expressing molecular clones encoding either WT Gag-mEos3.2 or CA/NC mutant Gag-mEos3.2 
and lacking the vpu gene were fixed and imaged by conventional TIRF microscopy. (B) Cells expressing 
the indicated Gag-mEos3.2 constructs in the absence of Vpu were stained for tetherin and imaged by TIRF 
as in Figure 2.5, and super-resolution microscopy images were reconstructed as described in Materials and 
Methods. Representative images are shown for WT, PTAP
-
, and CA/NC Gag-mEos3.2. Magnified images 
for boxed areas in the left panels are shown on the right. Scale bars are 2 m for the left panels and 500 nm 
for the right panels. (C) Images of five cells per condition were acquired in each of two independent 
experiments (total 10 cells) and used for measurement of Gag-tetherin cross-correlation. Integrated cross-
correlation was calculated as described in Materials and Methods and is shown as mean ± SEM. *, 









significantly less tetherin coclustered with Gag (Figure 2.7B and C). Notably, as was 
observed in the siRNA experiments (Figure 2.5F), intermediate levels of tetherin-Gag 
coclustering were detected under these conditions in which Gag interactions with Tsg101 
or Alix were blocked genetically rather than by reducing the expression levels of these 
host factors. Third, we observed negligible levels of tetherin-Gag coclustering with P99A 
and EE75,76AA Gag-mEos3.2, which are not significantly more than that seen with 
CA/NC Gag-mEos3.2. The intermediate levels of tetherin recruitment observed upon 
disruption of Gag-ESCRT interactions (second category) were significantly greater than 
that seen for CA mutants that fail to induce membrane curvature (P99A and EE75,76AA 
Gag-mEos3.2) and CA/NC Gag-mEos3.2 (third category) (Figure 2.7C).  
These results indicate that intermediate levels of tetherin recruitment, which are 
sufficient for virus release inhibition (Figure 2.6), are observed when Tsg101 or Alix are 
depleted (Figure 2.5) or when ESCRT-interacting motifs of Gag are disrupted (Figure 
2.7). In addition, these intermediate levels of tetherin recruitment are abolished by 
mutations that disrupt either Gag multimerization or virus-induced membrane curvature 
(Figure 2.7). Given that the two CA N-terminal domain mutants used in this study (P99A 
and EE75,76AA) still contain the intact major Gag-multimerization domains (the CA C-
terminal domain and the NC domain) and show dense patches of multimerized Gag at the 
plasma membrane by electron microscopy (Figure 2.3), it is likely that membrane 






 HIV-1 encodes four accessory genes that have been implicated in combating host 
defense responses (Vif, Vpr, Vpu, and Nef) [82], exemplifying the necessity for immune 
evasion by successful viral pathogens. Such evolutionary interplay between virus and 
host is epitomized by the relationship between HIV-1 Vpu and human tetherin. Tetherin 
appears to have arisen early in mammalian evolution and remains a potent inhibitor of 
many enveloped viruses [20]. Considering the broad range of susceptible viruses, it is 
unlikely that tetherin recruitment is mediated by a direct interaction between tetherin and 
the Gag polyprotein. In support of this notion, we and others have observed that tetherin 
potently inhibited release of Gag derivatives lacking the juxta-membrane MA domain 
that could potentially interact with the short cytoplasmic tail of tetherin [83] (unpublished 
data). Instead of the MA sequence, this study identified amino acid residues in the CA N-
terminal domain and late domain motifs as molecular determinants for recruitment of 
tetherin to HIV-1 assembly sites at the plasma membrane. Importantly, mutations in the 
former impair Gag-induced membrane curvature, whereas those in the latter disrupt Gag-
ESCRT interactions. Therefore, these results support a model in which both membrane 
curvature and the presence of ESCRT promote tetherin accumulation to the assembly 
sites of HIV-1.         
We and others have hypothesized that tetherin recruitment may be mediated by 
lipid rafts on the plasma membrane. This seemed an attractive model because lipid rafts 
are incorporated into the membranes of many enveloped viruses. Another line of 
evidence in support of this hypothesis is the presence of tetherin in Triton X-insoluble 
membrane fractions [16, 18]. Even though a study on tetherin chimeras in which the GPI 
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anchor is replaced with a heterologous transmembrane domain showed that lipid raft 
association measured by detergent resistance is not sufficient [84], it was possible that 
association of tetherin with lipid rafts may play an important role. In the present study, 
however, by an antibody copatching assay we found that tetherin itself does not appear to 
associate strongly with multiple lipid raft markers (CD55, CD59, NFP-GPI, and NFP-
HATM) at the plasma membrane, all of which were previously shown to copatch strongly 
with WT Gag [26]. Another recent study also failed to detect significant colocalization 
between tetherin and a lipid raft marker GM1 by super-resolution microscopy techniques 
[10]. It is a valid concern that tetherin localization in the copatching assay may not reflect 
its native partitioning to microdomains unlike other raft proteins, since antibody 
treatment could alter tetherin function [60]. However, we also found that cholesterol 
depletion that disrupts integrity of lipid rafts has little effect on tetherin function. These 
results indicate that, although tetherin may still have an affinity for a specific subset of 
lipid rafts before its recruitment to virus assembly sites, such prior association with 
cholesterol-dependent lipid rafts is not required for tetherin antiviral function. 
Conventional and super resolution microscopy of Gag late domain mutants did, 
however, reveal a potential role for Gag-ESCRT interaction in enhancing tetherin 
recruitment to virus assembly sites in HeLa and T cells. Moreover, siRNA knockdown 
experiments confirmed that expression of both Tsg101 and Alix is required for the high 
levels of tetherin recruitment seen with WT Gag in HeLa cells. A previous study that 
analyzed nascent particles formed by PTAP
-
 Gag using immuno-SEM showed that WT 
tetherin does not appear to specifically accumulate at HIV-1 assembly sites [9]. Although 
WT Gag particles were not examined in that study, this observation is consistent with our 
68 
 
findings supporting a role for ESCRT in enhancing tetherin recruitment. Notably, and 
somewhat unexpectedly, the high levels of tetherin recruitment, which is manifested as 
tetherin-Gag colocalization detected by confocal microscopy, was dispensable for the full 
activity of virus release restriction.  
 Conventional and super resolution microscopy showed largely consistent results 
for most conditions. However, a triple Gag mutant defective in Alix interaction (CCY
-
) 
did not show a significant decrease in tetherin recruitment as quantified by Pearson’s 
coefficients of confocal images in HeLa cells, but did show significantly less coclustering 
with tetherin in HeLa cells by super-resolution microscopy analysis. While the origin of 
this difference remains unclear, it is possible that tetherin accumulates at or near the 
relatively large protrusive tubular membrane structures containing CCY
-
 Gag patches 
(Figure 2.3A) and thereby leads to the WT-level Pearson’s correlation coefficient values 
without actually associating with Gag clusters. It is also possible that these structures may 
form more frequently on the top surface of cells than on the bottom surface.  Indeed, we 
noticed that the Gag-positive tubular structures were detected on the bottom surface of 
cells imaged by super-resolution microscopy but only in the minority of cells 
(unpublished observation). Super-resolution analyses also revealed the difference in the 
levels of tetherin association with Gag mutants defective in ESCRT interactions versus 
those defective in inducing membrane curvature (Figure 2.7), which were 
indistinguishable in confocal microscopy analyses (Figure 2.3). Analysis of a 
multimerization-defective Gag (CA/NC Gag) mutant by super-resolution techniques also 
suggests the presence of Gag clusters on the cell surface (Figure 2.7). These observations, 
together with recent studies [10, 85, 86], highlight the utility of using super-resolution 
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microscopy to analyze virus-host interactions at the level of single virus assembly sites 
and to study early as well as late events in virus assembly.  
While the exact mechanism by which Tsg101 and Alix enhance tetherin 
recruitment to HIV-1 assembly sites remains to be elucidated, this activity likely occurs 
later in the assembly process, since tetherin is not recruited to the same extent by Gag 
mutants defective in inducing membrane curvature (Figure 2.4) despite the presence of an 
intact late domain in these mutants. Although HIV-1 Gag may associate with Alix early 
during assembly as seen with EIAV Gag, recruitment of downstream ESCRT 
components occurs later during the process [87, 88]. It is possible that ESCRT proteins 
may form a barrier, which limits diffusion away from budding viruses. Notably, while 
recruitment of Tsg101 and Alix and hence the ESCRT machinery to assembly sites 
appears to be important for enhanced tetherin recruitment, formation of the pinching off 
machinery composed of ESCRT-III is not sufficient. In Alix-depleted cells, the ESCRT-
III machinery is still functional [79, 80] (Figure 2.6), but the high levels of tetherin 
recruitment were not observed (Figure 2.5), indicating that this recruitment relies not only 
on the presence of ESCRT, but the presence of Alix or Alix-dependent process.   
Although the additional level of tetherin recruitment promoted by Gag-ESCRT 
interactions appears unnecessary for tetherin-mediated inhibition of HIV-1, which forms 
relatively small, spherical virus particles, it is possible that larger enveloped viruses, such 
as filamentous orthomyxoviruses or filoviruses, may require greater amounts of tetherin 
to prevent their escape from infected cells. It would be interesting to examine the effects 
of ESCRT disruption on tetherin-mediated inhibition of these viruses. 
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Our findings did, however, provide evidence that Gag-induced membrane 
curvature results in intermediate levels of tetherin recruitment, which are sufficient to 
inhibit virus release. This result suggests that tetherin itself may be attracted to membrane 
curvature. Unfortunately, the contribution of membrane curvature to the antiviral effect 
of tetherin cannot be examined using virus release assays. This is because in contrast to 
Gag-ESCRT interactions, membrane curvature is inseparable from virus particle release. 
Most membrane-curvature-defective Gag constructs fail to release VLPs regardless of 
Vpu expression (e.g., EE75,76AA Gag-YFP). Some curvature mutants (e.g., P99A Gag-
YFP) release a low level of VLPs, but this is through assembly, budding, and release that 
proceed in an apparently WT-like manner albeit less frequently (unpublished data) [26].  
As such, the low but detectable VLP release of P99A Gag-YFP was dependent on Vpu 
(unpublished data). Thus, in either case, it is not feasible to examine using Gag mutants 
to what extent membrane curvature promotes tetherin-mediated inhibition of virus 
release. However, it may be possible to address this point using tetherin mutants. There 
are several examples of cellular proteins that are able to both sense and manipulate 
membrane curvature via protein domains that form curved structures [89, 90]. 
Intriguingly, based on crystallography analyses, it was hypothesized that a tetherin 
tetramer can form curved assemblies that may sense membrane curvature [14]. In this 
regard, it will be interesting to examine requirements for recruitment of tetherin mutants 
that can dimerize but are predicted to fail to oligomerize [13, 15, 86]. All enveloped 
viruses that assemble at the plasma membrane, whether dependent upon ESCRT 
machinery or not, must deform this membrane during budding, and therefore the 
membrane-curvature-dependent tetherin recruitment can explain the broad range of 
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tetherin-susceptible viruses. It remains to be seen whether tetherin distinguishes virus-
induced and non-virus-induced membrane curvature and whether higher levels of tetherin 
recruitment, which are dependent on ESCRT engagement, are relevant in the context of 
other enveloped viruses. 
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Characterization of HIV-1 interactions with uropod-directed 




 The process of HIV-1 assembly begins with binding and targeting of the major 
viral structural protein, Gag, to the plasma membrane of the host cell in most cell types. 
This complex and highly-regulated interaction involves the participation of various 
membrane components. After membrane binding has taken place, Gag is able to recruit 
the viral envelope protein, Env, as well as interact with several cell-surface proteins, 
some of which constitute distinct microdomains on the plasma membrane. Gag is also 
capable of reorganizing some of these domains through an undefined mechanism. In 
polarized T cells, which are a natural host of HIV-1 infection in vivo, Gag has been 
shown to interact with a subset of microdomains which polarize to a rear-end protrusion 
termed the uropod. In the current study, we employ quantitative super-resolution 
localization microscopy to investigate and define the underlying mechanism by which 
Gag interacts with uropod-directed microdomain proteins. We also use more 




 By super-resolution localization microscopy and cross-correlation analysis, we 
have determined that basic residues in the matrix domain of Gag as well as basic residues 
in the cytoplasmic tail of PSGL-1 are required for efficient co-clustering of these 
proteins. We have also determined that Ezrin, Radixin, and Moesin proteins do not play a 
role in this interaction and are slightly inhibitory. Finally, we have determined that 
expression of uropod-directed proteins PSGL-1, CD43, CD44, and ICAM-3 moderately 
reduces infectivity and cell-to-cell transfer of HIV-1. 
 
Introduction 
 As an enveloped virus, HIV-1 interacts with and assembles at the plasma 
membrane in most cell types. The process of membrane binding is driven exclusively by 
the matrix (MA) domain of the Gag precursor polyprotein (Pr55), which initiates and 
coordinates viral assembly at the plasma membrane. Initial membrane binding and 
targeting of Gag are mediated by co-translational, N-terminal myristoylation of Gag as 
well as specific interactions between the highly-basic region (HBR) of the MA domain 
and the plasma-membrane specific phospholipid, phosphatidylinositol-(4,5)-bisphosphate 
PI(4,5)P2 [1-5].  
RNA is able to inhibit non-specific membrane binding of Gag; however, this 
inhibition can be overcome by PI(4,5)P2 interaction [6, 7]. Additional evidence has 
suggested that other acidic lipids present in the plasma membrane, such as 
phosphatidylserine (PS), as well as uncharged, zwitterionic lipids, such as  
phosphatidylcholine (PC) and phosphatidylethanolamine (PE), may also contribute to and 
stabilize membrane binding of Gag [8, 9]. It has also been proposed that cholesterol and 
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acyl chain composition may influence the ability of Gag to bind to these lipids in cells 
[8].  Given that most of these studies were carried out using simple, defined lipid 
mixtures and Gag synthesized in vitro, it remains to be seen which of these interactions 
are critical for HIV-1 assembly at intact cellular membranes.  
Once membrane binding has taken place, Gag associates with cholesterol-rich 
areas of the membrane which are resistant to detergent solubilization, termed lipid rafts 
[10]. This association has been shown to enhance multimerization of Gag, which in turn 
facilitates virus assembly [11] . 
Viral assembly involves a coordinated and highly regulated process by which Gag 
is able to recruit all essential viral components into spherical virus particles of 
approximately 100 nm in diameter, which are ultimately released from infected cells with 
the help of cellular machinery. This process includes incorporation of the viral envelope 
glycoprotein (Env), encapsidation of viral genomic RNA (gRNA), and incorporation of 
other viral and cellular proteins [12]. During assembly, Gag has been observed to interact 
with plasma membrane microdomains such as tetraspanin-enriched microdomains 
(TEMs) and certain uropod-directed microdomains (UDMs) which are present in 
polarized T cells [13-17]. Gag has also been observed to actively reorganize these 
domains in ways which do not occur in uninfected cells [18-20]. 
T cells, which are a natural host of HIV-1 infection in-vivo, are highly motile and 
exhibit polarized morphology in secondary lymphoid tissues, where HIV-1 dissemination 
is thought to occur [21]. Previous studies conducted in our lab have demonstrated that 
Gag interacts with certain microdomains, termed class I UDMs in this thesis, composed 
of PSGL-1, CD43, and CD44 [16]. While this association is probably not required for 
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polarization of Gag to uropods, these interactions have been observed prior to cell 
polarization. Also, polarization of both Gag and UDMs is dependent upon the actin-
myosin system [16]. 
Surprisingly, Gag has also been shown to exclude a second class of UDMs, 
termed class II UDMs, from virus assembly sites. CD59, ICAM-1, and ICAM-3 have all 
been observed to polarize to uropods, but not to associate with Gag in unpolarized T 
cells. Furthermore, ICAM-3, which is normally associated with the class I UDM protein 
CD44 in uninfected cells, is actively removed from these domains in the presence of Gag 
through an unknown mechanism [20]. 
Transmission of virus from infected cells to uninfected cells likely occurs at a 
virus-induced structure termed the virological synapse (VS). Formation of the VS is 
primarily mediated by interactions between Env on donor cells and CD4 on target cells 
[22]; however, synapses have also been observed in the absence of Env [23]. The VS is 
thought to be somewhat analogous to the well characterized immunological synapse (IS), 
which forms between antigen presenting cells and T cells [24]; however, it lacks the high 
degree of spatial organization seen in the IS [25]. Both are thought to be composed of 
critical receptor-ligand interactions, as well as additional adhesion molecules which 
promote sustained cell-to-cell contact [26].  
Understanding the interactions which facilitate cell-to-cell virus transfer is of 
great importance in HIV research because this method of infection is much more efficient 
than infection by cell-free virus [27]. In addition, cell-to-cell transfer has been shown to 
be resistant to anti-viral drugs and neutralizing antibodies [28-31]. In order to treat and 
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prevent HIV infection, we must find ways to target cell-to-cell virus transmission, as it is 
likely the primary route of HIV dissemination in vivo. 
While the precise role of UDMs in viral replication and dissemination remains to 
be elucidated, it is likely that HIV-1 has evolved to preferentially incorporate certain 
uropod-directed proteins at virus assembly sites for some purpose. Given that these 
transmembrane proteins all possess large extracellular domains, we speculate that their 
incorporation into viral envelopes may influence intercellular transfer of virus from 
infected to uninfected cells. In this study, we employ quantitative super-resolution 
localization microscopy methods to elucidate the mechanism of HIV-UDM interactions. 
We also use more conventional virological methods to determine the consequences of 
Gag-UDM interactions in viral replication. 
 
Materials and Methods 
Plasmids and siRNA 
pNL4-3/Gag-mEos3.2 was generated by replacing the YFP coding sequence of 
pNL4-3 Gag-Venus with that of mEos3.2, with the initiator methionine residue removed, 
as in the constructs described in Chapter 2 of this thesis. pNL4-3/Fyn(10)/Gag-mEos3.2, 
pNL4-3/Fyn(10)/6A2T/Gag-mEos3.2, and pNL4-3/Fyn(10)/HBRswitch/Gag-mEos3.2 
were constructed similarly from pNL4-3/Gag-Venus versions of these constructs, which 
were described previously [19, 20].  
A plasmid encoding a full-length cDNA clone of human PSGL-1 (transcript 
variant 2), pCMV6-AC/PSGL-1, was obtained from Origene (NM_003006.3, Rockville, 
MD). pCMV6/empty was created by digesting pCMV6-AC/PSGL-1 with AgeI to remove 
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the entire MCS, followed by re-ligation of the vector. pCMV6-AC/PSGL-1 C310A and 
CT (with a stop codon in place of L331) constructs were generated by standard PCR 
mutagenesis techniques. pCMV6-AC/PSGL-1 3A and 6A constructs were generated by 
the following substitutions (mutations in bold): 334-338 RLSRK  ALSAA (3A) and 
385-394 EPREDREGDD  APRAARAGAA (6A), using standard PCR mutagenesis 
techniques. 
Plasmids encoding full length cDNA clones of human CD43 (NM_003123), 
pCMV6-XL5/CD43, CD44 (NM_000610), pCMV6-XL5/CD44, ICAM-1 (NM_000201), 
pCMV6-XL5/ICAM-1, and ICAM-3 (NM_002162.2), pCMV6-AC/ICAM-3 were 
obtained from Origene (Rockville, MD). The chimeric constructs pCMV6-AC /ICAM-1-
PCT and pCMV6-AC/ICAM-3-PCT were constructed by inserting the sequences 
encoding the extracellular and transmembrane portions of ICAM-1 and ICAM-3 
respectively into pCMV6-AC/PSGL-1, in place of the PSGL-1 extracellular and 
transmembrane portions by standard molecular cloning techniques. The sequence of 
ICAM-1-PCT is as follows (ICAM-1 residues in bold): MAPSSP…LSTYLYAVRLSR… 
The sequence of ICAM-3-PCT is as follows (ICAM-3 residues in bold): 
MATMVP…ALMYVFAVRLSR… 
 siRNA sequences directed against Ezrin (CAAGAAGGCACCUGACUUU), 
Radixin (GAACUGGCAUGAAGAACAU), and Moesin (AUAAGGAAGUGCAUAA 
GUC) were described previously [32]. A control siRNA, which does not target any 
known human mRNA sequences (UUCUCCGAACGUGUCACGU), was also used [33]. 





 A monoclonal mouse antibody directed against human PSGL-1 (clone KPL-1), 
was obtained from BD Biosciences (San Jose, CA). This antibody was directly labeled 
with Alexa Fluor 647 using an antibody labeling kit obtained from Life Technologies 
(Carlsbad, CA). Rabbit antibodies directed against human Ezrin, Radixin, and Moesin 
proteins were obtained from Cell Signalling Technology (Beverly, MA). Anti-HIV-Ig 
was obtained from the NIH AIDS Research and Reference Reagent Program (ARRRP). 
 
Cells 
 HeLa cells were maintained in DMEM supplemented with 5% FBS, Pen/Strep, 
and L-glutamine. For STORM analysis, cells were plated at a density of 4.2x10
4
 cells per 
well in #1.5, 4-chamber coverslips from Fisher Scientific (Pittsburgh, PA). After 
overnight incubation, cells were transfected with 1 g pNL4-3/Gag-mEos3.2 plasmids 
and 50 ng pCMV6-AC/PSGL-1 plasmids per well, using Lipofectamine 2000 reagent, 
according to the manufacturer’s instructions (Life Technologies, Carlsbad, CA). MA-
replacement constructs were additionally supplemented with 0.5 g of pNLA-1 [34], a 
plasmid which encodes all viral proteins except Gag and GagPol, because these 
constructs display a splicing defect and only express Gag (IBH and JRG, unpublished 
ovservations). Cells were then incubated for 16 hours prior to fixation with 1X PBS + 4% 
PFA + 0.1% glutaraldehyde for 10 minutes followed by immunostaining with anti-PSGL-
1 antibody. 
 293T cells were maintained in DMEM supplemented with 10% FBS, Pen/Strep, 
and L-glutamine. SupT1 and CEM-GFP cells were maintained in RPMI supplemented 
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with 10% FBS, Pen/Strep, and L-glutamine. CEM-GFP cell media was additionally 
supplemented with 500 g/ml G418 to maintain LTR-dependent GFP expression. 
 
Super-Resolution Localization Microscopy and Image Processing 
 Sample preparation, imaging conditions, and data analysis methods are described 
in detail in chapter 2 of this thesis. To compare total clustering in cross-correlation 
analyses, area under cross-correlation curves was integrated from 0-200 nm. 
 
siRNA Knockdowns 
 For siRNA-mediated depletion of Ezrin, Radixin, and Moesin, HeLa cells were 
plated at a density of 10
5
 cells per well in 24-well culture plates (Corning, Fairport, NY). 
After overnight incubation, cells were transfected with 20 pM siRNA (40 pM for Ezrin-
directed siRNA) using Lipofectamine 2000, according to the manufacturer’s instructions 
(Life Technologies, Carlsbad, CA). After 24 hours, cells were typsinized, counted, and 
plated at a density of 4.2x10
4
 cells per well in #1.5, 4-well chambered coverslips (Fisher 
Scientific, Pittsburgh, PA). Cells were incubated for an additional 24 hours before 
transfection as described above, giving a total of 64 hours post-transfection by siRNA 
and 16 hours post-transfection by PSGL-1 and Gag-mEos3.2 plasmids before fixation. 
 
Infectivity Assay 
 293T cells were plated at a density of 5.6x10
5 
cells/well in 6-well culture plates 
(Corning Inc., Corning, NY), incubated overnight and transfected with 2 g pNL4-3 and 
a total of 300 ng of plasmids encoding indicated proteins using polyethylenimine (PEI, 
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Polysciences, Warrington, PA), followed by 48 hour incubation at 37C. Culture 
supernatants were collected, cleared by low-speed centrifugation and filtered through 
0.45 m filters, followed by centrifugation at 35,000 rpm for 45 minutes at 4C. Virus 
pellets were resuspended in 100 l RPMI + 10% FBS. 10 l of each virus stock was then 
added to 2x10
5
 CEM-GFP cells in 12-well culture plates (Corning Inc., Corning, NY) and 
incubated for 48 hours at 37C. Cells were fixed and analyzed by FACS. Relative 
amounts of virus production were determined by Western blotting of virus lysates with 
anti-HIV Ig, and quantitation of virus-associated p24. 
 
Cell-to-cell Transfer Assay 
HeLa cells were plated at a density of 5.6x10
5 
cells/well in 6-well culture plates 
(Corning Inc., Corning, NY), incubated overnight and transfected with 2 g pNL4-
3/Gag-YFP and a total of 300 ng of plasmids encoding indicated proteins using 
Lipofectamine 2000 (Life Technologies, Carlsbad, CA), followed by 16 hour incubation 
at 37C. Culture media was removed and cells were washed once with media. Next, 
4x10
5
 SupT1 cells were added to each well in RPMI + 10% FBS. Cells were incubated 
for 3 hours at 37C before being removed from wells, fixed, and analyzed by FACS. 
HeLa and SupT1 cells were separated by differences in forward and side scattering. 
 
Results 
 We have previously shown that HIV-1 Gag interacts with class I UDM proteins 
PSGL-1, CD43, and CD44 in unpolarized T cells [16, 20]. This interaction was found to 
be dependent upon the charge, but not specific amino acid sequence of the MA HBR 
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[20]. These previous studies were performed using an antibody copatching assay [19], 
which clusters proteins into visible patches that can be observed by traditional, 
diffraction-limited microscopy. However, this technique may not reflect the native 
distribution of proteins in live cells because proteins of interest are clustered by primary 
and secondary antibodies prior to fixation. To analyze the interactions between HIV-1 
Gag and UDM proteins in greater detail, without the use of antibody copatching, we 
employed two-color super-resolution localization microscopy techniques (described in 
chapter 2 of this thesis), which have been used previously by our group and others to 
study virus-host interactions [35-37]. 
 HeLa cells constitute a suitable model system in which to conduct these 
experiments because they are highly adherent, support HIV-1 virus production, and do 
not express endogenous UDM proteins. Although T cells are a more natural host for 
HIV-1 replication in vivo, they cannot be imaged by TIRF illumination unless adhered to 
coverglasses by immobilized extracellular matrix proteins or poly-L-lysine. This has the 
potential to alter the distribution and inhibit normal diffusion of UDM proteins, many of 
which possess adhesive properties. HeLa cells are also very amenable to transfection by 
plasmid DNA and siRNA, and therefore allow for analysis of the contributions of 
individual UDM proteins to HIV-1 assembly and transmission. 
We first sought to determine whether Gag-UDM interactions occur in HeLa cells 
in a similar manner to that observed in T cells. It is possible that these interactions are 
dependent on certain factors which are present in T cells but absent in adherent cell lines. 
To determine whether these interactions take place in HeLa cells, we expressed PSGL-1 
along with three Gag constructs fused to the photo-switchable, monomeric fluorescent 
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protein mEos3.2 [38]. The first, Fyn(10)/Gag (when fused to YFP) has been shown to 
behave similarly to wild type Gag, with respect to UDM association [16]. The second, 
Fyn(10)/6A2T/Gag, is a construct in which the 8 basic residues of the HBR, which 
 
 
Figure 3.1. The basic charge of MA HBR promotes co-clustering of Gag and PSGL-1 in HeLa cells. 
HeLa cells were transfected with plasmids encoding Gag-mEos3.2 fusion constructs and wild type PSGL-1. 
Cells were fixed and stained for PSGL-1 with a monoclonal antibody against PSGL-1, which was directly 
labeled with AlexaFluor 647, and imaged by TIRF microscopy in reducing buffer (7,500 image frames per 
cell). (A) Reconstructed images were produced as described in Materials and Methods in chapter 2 of this 
thesis. Images show Gag-mEos3.2 in green and PSGL-1 in red. Scale bar = 500 nm. (B) Cross-correlation 
curves express co-clustering of molecules as a function of radius. (C) Total co-clustering was calculated by 
integrating area under cross-correlation curves from 0-200 nm as described in Materials and Methods in 
chapter 2 of this thesis. (B-C) Results shown include a total of 10 cells per condition from 2 independent 
experiments. Values shown indicate mean values ± sem. *significantly less than Fyn(10), p < 0.05. 
**significantly greater than Fyn(10)-6A2T and significantly less than Fyn(10), p < 0.05. 
 
facilitate interactions between Gag and PI(4,5)P2 have been replaced with neutral amino 
acids [20]. The third, Fyn(10)/HBRswitch/Gag, is a construct in which the identity of the 8 
90 
 
basic residues in the HBR has been exchanged (RK and KR). This construct has 
been shown to restore Gag-UDM interactions to similar levels to those observed with 
wild type and Fyn(10) Gag constructs by antibody copatching assay [20]. 
 When expressed in HeLa cells, we observed that all of these constructs localize to 
the plasma membrane, as did PSGL-1. We found that, consistent with our findings in T 
cells, Fyn(10)/Gag-mEos3.2 clustered highly with PSGL-1. We also observed that 
Fyn(10)/6A2T/Gag-mEos3.2 showed very low levels of clustering with PSGL-1, and co-
clustering was partially restored by the HBRswitch mutation, although not to the same level 
as when the wild type HBR sequence was present (Figure 3.1). These results indicate  
that Gag is able to associate with PSGL-1, a class I UDM protein, when expressed in 
HeLa cells. They also show that viral determinants of this interaction are similar to those 
observed in T cells.  
Although exchanging the identity of the basic residues within the HBR did 
partially restore PSGL-1 co-clustering, it was not completely restored to wild type levels. 
While this mutant retains the same overall charge of the HBR, unlike wild type Gag, it is 
unable to bind to liposomes containing PI(4,5)P2 without prior RNAse treatment [20]. 
While wild type Gag is able to interact specifically with PI(4,5)P2, the HBRswitch mutant 
is likely to only interact with PI(4,5)P2 through non-specific, electrostatic interactions. 
The finding that this mutant also displays lower clustering with PSGL-1 may suggest that 
PI(4,5)P2 plays a role in recruitment of this protein to HIV-1 assembly sites. This 
hypothesis is also consistent with the observation that PI(4,5)P2 depletion exerts a much 
more potent effect in HeLa cells than in T cells [1, 39]. 
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 In order to better understand how Gag recruits class I UDM proteins to virus 
assembly sites, we sought to identify which components of PSGL-1 are necessary for this 
interaction. Because PSGL-1 is always present as a dimer in cells, we asked whether 
dimerization is necessary for Gag-PSGL-1 interaction. To do this, we utilized a 
previously characterized mutant (C310A) which abolished dimerization of PSGL-1 [40]. 
We found that this mutation did not significantly decrease Gag-PSGL-1 co-clustering,  
 
 
Figure 3.2. The cytoplasmic tail of PSGL-1, not dimerization, is required for co-clustering with Gag. 
HeLa cells were transfected with plasmids encoding wild type Gag-mEos3.2 and PSGL-1 mutants. Cells 
were prepared, imaged, and analyzed as in Figure 3.1. (A) Reconstructed images show Gag-mEos3.2 in 
green and PSGL-1 in red. Scale bar = 500 nm. (B) Cross-correlation curves express co-clustering of 
molecules as a function of radius. (C) Total co-clustering was calculated by integrating area under cross-
correlation curves from 0-200 nm. (B-C) Results shown include a total of 10 cells per condition from 2 
independent experiments. Values shown indicate mean values ± sem. *significantly less than WT, p < 0.05. 




ruling out a role for dimerization (Figure 3.2). Next, we sought to determine whether the 
cytoplasmic tail of PSGL-1, which may interact directly or indirectly with Gag or other  
viral components, is required for Gag-PSGL-1 interaction. We found that deletion of the 
cytoplasmic tail of PSGL-1 (truncated after residue 331) substantially reduced Gag-
PSGL-1 interaction, although this mutant is expressed highly on the plasma membrane 
(Figure 3.2). This experiment identifies the cytoplasmic tail of PSGL-1 as the major 
determinant of Gag-PSGL-1 co-clustering. Given that co-clustering was not completely 
abolished by this truncation, the extracellular and transmembrane domains of this protein 
may also contribute to co-clustering with Gag. 
 Next, we sought to determine which features of the cytoplasmic tail of PSGL-1 
are necessary for its recruitment to HIV-1 assembly sites. We generated two hypotheses 
which could be tested by mutagenesis of the cytoplasmic tail of PSGL-1. Given that basic  
residues within the HBR are critical for this interaction, we speculated that an acidic 
stretch near the C-terminus of the cytoplasmic tail of PSGL-1 may be interacting directly 
with the HBR of the MA domain. To test this hypothesis, we generated a mutant,  
PSGL-1/6A, in which these 6 residues have been replaced with an uncharged amino acid, 
alanine (EPREDREGDD  APRAARAGAA).  
Our second hypothesis was based on the observation that PSGL-1, CD43, and 
CD44 all possess basic amino acids immediately C-terminal to their transmembrane 
domains, near the cytoplasmic leaflet of the lipid bilayer. Given that Gag can bind to 
acidic lipids such as PI(4,5)P2 and PS through the HBR [3, 6], we speculated that 
clustering of acidic lipids at assembly sites by multimerizing Gag molecules may attract 
PSGL-1 and possibly also CD43 and CD44. To test this hypothesis, we generated a 
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mutant, PSGL-1/3A, in which three juxta-membrane basic residues have been replaced 
with alanine (RLSRK  ALSAA). 
 When expressed in HeLa cells, we found that PSGL-1/6A co-clusters with Gag-
mEos3.2 to a similar extent as wild type PSGL-1, while co-clustering was significantly 
reduced by the 3A mutation (Figure 3.3). These results indicate that a basic motif near the 
plasma membrane is significantly enhances co-clustering of PSGL-1 with HIV-1  
 
 
Figure 3.3. Basic residues in the cytoplasmic tail of PSGL-1 enhance co-clustering with Gag. 
HeLa cells were transfected with plasmids encoding wild type Gag-mEos3.2 and PSGL-1 mutants. Cells 
were prepared, imaged, and analyzed as in Figure 3.1. (A) Reconstructed images show Gag-mEos3.2 in 
green and PSGL-1 in red. Scale bar = 500 nm. (B) Cross-correlation curves express co-clustering of 
molecules as a function of radius. (C) Total co-clustering was calculated by integrating area under cross-
correlation curves from 0-200 nm. (B-C) Results shown include a total of 10 cells per condition from 2 
independent experiments. Values shown indicate mean values ± sem. *significantly less than WT, p < 0.05. 




assembly sites. They also rule out a direct interaction between the highly-acidic  
C-terminus of PSGL-1 and the basic residues of the MA HBR. Although co-clustering of 
Gag and PSGL-1 was not completely abolished by the 3A mutation, it was substantially  
reduced compared to wild type PSGL-1. This may indicate the presence of additional 
determinants within the cytoplasmic tail of PSGL-1, which promote co-clustering with 
Gag, however the “RLSRK” motif is likely the major determinant of this interaction.  
Interestingly, we found that PSGL-1/6A and CT mutants are very highly 
expressed at the plasma membrane, as seen by microscopy (Figures 3.2 and 3.3) and 
FACS analysis (data not shown). This may indicate that the acidic motif 
“EPREDREGDD” may constitute a sorting or endocytic signal which regulates cell-
surface levels of this protein. This observation also demonstrates the insensitivity of 
cross- correlation methods used in this thesis to relative protein expression levels. Both  
the 6A and CT mutants were more highly expressed at the cell surface than wild type 
PSGL-1, while one of them (CT) did not co-cluster highly with Gag-mEos3.2. 
The ERM family of proteins, composed of Ezrin, Radixin, and Moesin (also 
related to Merlin and Band 4.1) interact with the actin cytoskeleton as well as plasma 
membrane by binding to plasma membrane proteins and phospholipids, including 
PI(4,5)P2 [41]. These proteins have been seen to assume both a folded, inactive 
confirmation in the cytosol, as well as an active, phosphorylated form capable of linking 
the plasma membrane and actin cytoskeleton. These proteins play important roles in cell 
morphology, polarity, and motility [42]. 
 Of interest to this study, several uropod-directed proteins contain binding sites for 
ERM proteins, including PSGL-1 [43, 44], CD43 [45], CD44 [46], ICAM-1 [47], and 
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ICAM-3 [43]. In particular, binding of PSGL-1 to Ezrin is mediated by an “RK” motif 
located near the plasma membrane. Given that these residues have been mutated in the 
PSGL-1/3A mutant, and that this mutation abolished PSGL-1-Ezrin interaction [44], we 
sought to determine whether ERM proteins play a role in Gag-PSGL-1 interaction. To 
accomplish this, we performed siRNA-mediated depletion of Ezrin, Radixin, and Moesin 
proteins individually and in combination. Following this, we expressed wild type PSGL-1 
and Gag-mEos3.2 and performed STORM imaging and cross-correlation analyses. 
 
Figure 3.4. ERM proteins decrease co-clustering of Gag and PSGL-1. 
HeLa cells were transfected with indicated siRNA oligonucleotides, followed by transfection with plasmids 
encoding wild type Gag-mEos3.2 and PSGL-1. Cells were prepared, imaged, and analyzed as in Figure 3.1. 
(A) Reconstructed images show Gag-mEos3.2 in green and PSGL-1 in red. Scale bar = 500 nm. (B) Cross-
correlation curves express co-clustering of molecules as a function of radius. (C) Total co-clustering was 
calculated by integrating area under cross-correlation curves from 0-200 nm. (D) Western blots of Ezrin, 
Radixin, and Moesin from cells prepared under identical conditions to those used for microscopy. -tubulin 
is shown as a loading control. (B-C) Results shown include a total of 9 cells per condition from 2 
independent experiments. Values shown indicate mean values ± sem. *significantly greater than Non-




 We were able to achieve approximately 90% reduction in the levels of all 3 
proteins when depleted individually, and approximately 80% reduction when all 3 were 
depleted simultaneously as compared to non-target siRNA-treated cells and assessed by  
Western blotting (Figure 3.4D). Under these conditions, we observed that depletion of 
Ezrin, Radixin, or Moesin individually did not significantly affect Gag-PSGL-1 co-
clustering. In contrast, we observed that depletion of all three proteins led to a significant 
increase in Gag-PSGL-1 co-clustering (Figure 3.4A-C). Given the high degree of 
homology between these three proteins, it is not surprising that they may act redundantly, 
or compensate for the lack of one protein. These results indicate that not only are ERM 
proteins not required for Gag-PSGL-1 interaction, rather, they are slightly inhibitory 
when present in HeLa cells. 
 If ERM proteins are indeed inhibitory to PSGL-1 recruitment to virus assembly 
sites, it would be interesting to determine the effect of ERM over-expression on this 
process. If this effect is due to a competitive inhibition by ERM proteins, over-expression 
of these proteins would be expected to reduce co-clustering of Gag and PSGL-1. 
 There are several possible hypotheses which may explain this observation. First, 
the presence of ERM proteins and their interaction with basic residues in PSGL-1 
cytoplasmic tail may prevent interaction with Gag or some other component present at 
assembly sites. Second, binding of ERM proteins to PI(4,5)P2 at virus assembly sites may  
prevent efficient PSGL-1 recruitment. Third, uncoupling of the actin cytoskeleton and 
plasma membrane may allow for greater clustering of plasma membrane proteins and  
lipids, as has been predicted by biophysical simulations [48]. Fourth, linking of PSGL-1  
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to the cytoskeleton may inhibit its incorporation into virus assembly sites. This is 
consistent with the observation that the HIV-1 Nef protein appears to antagonize Ezrin 
[49], which is inhibitory to HIV-1 virus production [50]. 
 While it is likely that ERM interactions are necessary for polarization of both 
class I and class II UDM proteins in polarized T cells, it is unlikely that ERM proteins 
participate directly in polarization of HIV-1 Gag to uropods. This hypothesis is based on 
the observation that replacement of MA domain by the Fyn(10) sequence abolishes Gag-
UDM interactions (which depend on ERM proteins for polarization), but does not inhibit 
polarization of Gag [20]. Instead, it is more likely that Gag polarization is instead 
dependent upon bulk membrane flow, mediated by the actin-myosin system and ERM-
linked membrane proteins. This is supported by the finding that treatment of T cells with 
a myosin light chain kinase inhibitor, ML7, results in depolarization of Gag. Thus, while 
ERM proteins may be critical for maintaining rearward flow of membrane components 
toward the uropod, they may not be directly involved in HIV-1 polarization.  
Given that HIV-1 associates selectively with class I UDM proteins in polarized T 
cells, which are a natural host of HIV-1 infection in vivo, we sought to understand what 
role, if any, these interactions play in HIV-1 infection and dissemination. We 
hypothesized that because Gag-UDM interactions take place during viral assembly, these 
proteins may be involved in virus production, cell-to-cell transmission, or infectivity of 
virus particles. 
 To test these hypotheses, we first examined whether virus production is affected 
by expression of individual UDM proteins in HeLa and 293T cells. With the exception of 
CD44, which caused a modest reduction in virus production in 293T cells, all UDM 
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proteins examined in this study had no significant affect on virus production (data not 
shown). The defect in virus production observed in CD44-expressing 293T cells may 
possibly be accounted for by a specific cellular stress caused by over-expression of this 
protein. Another possibility is that because CD44 is a receptor for extracellular matrix 
components [51], its incorporation into virus particles may cause them to be retained 
within the extracellular matrix of producer cells. 
 We next tested whether UDM proteins have any effect on viral infectivity. This 
was done by deriving wild-type pNL4-3 virus stocks from 293T cells transfected with 
plasmids encoding UDM proteins of interest. These viruses were added to CEM-GFP 
cells, which express GFP under the control of the HIV-1 LTR. In the case of ICAM-1 and 
ICAM-3, we developed additional chimeric constructs (ICAM-1-PCT and ICAM-3-PCT)  
in which the cytoplasmic tails of these proteins was substituted with the cytoplasmic tail 
of PSGL-1. We reasoned that because the cytoplasmic tail of PSGL-1 contains the major 
determinants for co-clustering with Gag (Figure 3.2), it should allow for efficient 
incorporation of ICAM-1 and ICAM-3 into assembly sites and virus particles, which are 
not normally enriched at virus assembly sites in T cells [16, 20].  
Unexpectedly, expression of PSGL-1, CD43, and CD44, either individually or in 
combination, reduced viral infectivity to approximately 40% of control virus (Figure  
3.5A). We also observed a similar level of inhibition with ICAM-3, regardless of whether 
it contained its native cytoplasmic tail, or the cytoplasmic tail of PSGL-1 (Figure 3.5A). 
In contrast, we observed that ICAM-1 only reduced viral infectivity when it contained the  





Figure 3.5. PSGL-1, CD43, CD44, and ICAM-3 decrease infectivity and cell-to-cell transfer of HIV-1. 
(A) Virus was purified by ultracentrifugation from supernatants of 293T cells transfected with pNL4-3 and 
plasmids encoding the proteins indicated or an empty vector control. Virus was then added to CEM-GFP 
cells, which express GFP under the control of the HIV-1 LTR. Cells were incubated for 48 hours, followed 
by fixation and FACS analysis. Values shown are the mean percent GFP-positive cells, normalized to p24 
abundance in virus preparations (assessed by Western blotting). Values were further normalized to the 
empty vector control condition. Infection rate for the empty vector control was 5%.  (B) HeLa cells were 
transfected with pNL4-3/Gag-YFP and plasmids encoding indicated proteins. After 16 hour incubation at 
37C, cells were washed and 4x10
5
 SupT1 cells were added to each well. Cells were co-cultured for 3 
hours at 37C before being removed from wells, fixed, and analyzed by FACS. Values shown are the 
percent YFP-positive SupT1 cells normalized to the percent YFP-positive HeLa cells in each condition. 
Values were further normalized to the empty vector control condition. YFP positive rate of CEM-GFP cells 
for empty vector control was 58%. Error bars represent the variation in two independent experiments 
performed for each assay. 
 
 
As many UDM proteins are known to function as adhesive proteins, and 
participate in cellular contacts such as the immunological synapse [24], we examined 
whether they also modulate cell-to-cell transfer of virus particles. To test this hypothesis, 
we transfected HeLa cells with pNL4-3/Gag-YFP and plasmids encoding UDM proteins 
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of interest. Next, we added SupT1 T cells and co-cultured these cells for 3 hours. We 
have previously demonstrated efficient cell-to-cell transfer of Gag-YFP VLPs by this 
method [16]. Finally, cells were removed from culture plates, fixed and analyzed by 
FACS. 
By this assay, we observed that all UDM proteins tested, with the exception of 
ICAM-1, modestly inhibited virus transfer from HeLa to SupT1 T cells (Figure 3.5B). 
ICAM-1 appeared to have little effect on transfer efficiency whether it contained its 
native cytoplasmic tail or that of PSGL-1 (Figure 3.5B). Western blotting of these 
proteins in cell and virus lysates would be the best method to separate these possibilities, 
and would allow for direct measurement of rates of incorporation of these proteins into 
virus particles. Thus far, detection of these proteins under denaturing conditions has been 
not been achieved. 
 
Discussion 
 We have previously observed that HIV-1 Gag associates with uropod-directed 
microdomains composed of CD43, CD44, and PSGL-1 [16, 20]. This association occurs 
in both unpolarized and polarized T cells. Of note, these previous studies were conducted 
using an antibody copatching assay which may be prone to artifactual clustering of 
proteins. In the present study, we employ super-resolution microscopy methods which are 
able to resolve single virus assembly sites as well as single UDM proteins. These studies 
are carried out in cells which have been fixed prior to immunostaining, reducing the 
possibility of artifactual clustering of proteins. 
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 Consistent with previous findings, we found that association of Gag with PSGL-1 
is dependent upon the HBR of the MA domain. Replacing the 8 basic amino acids within 
the HBR substantially reduced Gag-PSGL-1 co-clustering. Exchanging the basic residues 
of the HBR from lysine to arginine and vice versa did still allow some recruitment of 
PSGL-1, but this was significantly less than that observed with wild type PSGL-1 (Figure 
3.1). Like wild type Gag, this construct is capable of binding to liposomes containing PS, 
after RNAse treatment [20]. This result suggests that the overall structure of the MA 
domain is not grossly perturbed by these substitutions. However, it is currently unknown 
whether this mutant is able to interact with PI(4,5)P2 after RNAse treatment [20]. It 
would be interesting to determine whether this mutant is unable to interact with PI(4,5)P2, 
while still retaining the same overall charge of the HBR. A lack of this specificity may 
support a role for PI(4,5)P2 in Gag-UDM interactions. 
 The observation that the HBRswitch construct is still able to recruit PSGL-1 to 
some level suggests that electrostatic interactions, rather than specific PI(4,5)P2 
interaction may be sufficient for recruitment of UDM proteins such as PSGL-1 to virus 
assembly sites. It will be interesting to determine whether this mutant is able to recruit 
CD43 and CD44 as well. It would also be interesting to determine whether these proteins 
are recruited independently, or whether CD43 and CD44 require PSGL-1 for efficient 
recruitment. 
 We next observed that the cytoplasmic tail of PSGL-1 contains the major 
determinants for co-clustering with Gag (Figure 3.2). Based on this finding, we speculate 
that the cytoplasmic tail of PSGL-1 may interact, either directly or indirectly, with Gag or 
some other component of HIV-1 assembly sites. While it is formally possible that the 
102 
 
extracellular domains of PSGL-1 and Env may interact and facilitate recruitment of 
PSGL-1 this is unlikely given the observation that Gag-PSGL-1 copatching still occurs in 
the absence of Env (GNL, unpublished observations). Furthermore, we found that basic 
residues within the cytoplasmic tail are responsible for the majority of Gag-PSGL-1 co-
clustering (Figure 3.3). While these residues also constitute a binding site for ERM 
proteins, we found that depletion of ERM proteins did not inhibit Gag-PSGL-1 co-
clustering. Rather, we found that depletion of Ezrin, Raxidin, and Moesin simultaneously 
enhanced this interaction slightly, but significantly (Figure 3.4). 
 Given the observations that basic residues are required on both sides of the 
interaction between Gag and PSGL-1, we hypothesize that there must be some acidic 
factor which links Gag and PSGL-1. Since these basic residues are likely positioned very 
close to the cytoplasmic leaflet of the plasma membrane, we further hypothesized that 
this unknown factor is likely an acidic lipid present in the inner leaflet of the plasma 
membrane. In a pilot experiment, we failed to observe any detectable co-clustering 
between PSGL-1 and the PH domain of PLC1, which specifically binds to PI(4,5)P2, or 
the C2 domain of Lactadherin, which specifically binds to PS (data not shown).This 
result suggests that PSGL-1 does not associate strongly with these lipids in Gag-negative 
cells, or does so at undetectable levels. Additionally it may suggest that either of these 
lipids, which are abundant in the plasma membrane, are not necessary for recruitment of 
PSGL-1 to virus assembly sites. Alternatively, it is possible that local clustering of acidic 




 We are currently in the process of separating these possibilities through the use of 
MA-replacement constructs. These chimeric Gag proteins contain peptides or protein 
domains known to interact with different subsets of plasma membrane lipids in place of 
the MA domain of Gag. This strategy has previously been employed successfully with 
the PH domain of PLC1[19]. If PSGL-1 is drawn to virus assembly sites by high local 
concentrations of acidic lipids rather than some specific sequence present in the MA 
domain, it should be detectable with these constructs, which entirely lack the globular 
head of the MA domain and all known natural determinants of Gag-membrane binding. 
 While it is known that several UDM proteins participate in adherence, motility, 
cell-to-cell contact, and cell signaling events in lymphocytes [24, 52-55], it is unknown 
what role, if any these proteins play in HIV-1 replication. CD43, CD44, and PSGL-1 co-
localize strongly with Gag and are likely incorporated efficiently into virus particles [16, 
20] (unpublished observations). In contrast, ICAM-1 and ICAM-3 have been shown to be 
excluded from virus assembly sites, and are unlikely to be efficiently incorporated into 
virus particles [16, 20]. 
 We speculated that as proteins with adhesive properties, class I UDM proteins 
may enhance infectivity or cell-to-cell transfer of virus between lymphocytes. However, 
we observed that both infectivity and cell-to-cell transfer of virus are modestly inhibited 
by CD43, CD44, and PSGL-1, whether expressed individually or in combination. We 
also observed that ICAM-3 modestly decreases infectivity and cell-to-cell transfer 
(Figure 3.6). Interestingly, we found that when containing the cytoplasmic tail of PSGL-
1, ICAM-1 also exerted a negative effect (Figure 3.6). This may indicate that ICAM-1 is 
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not normally incorporated to virus assembly sites and thus has no effect, but the chimera 
used in this study is efficiently incorporated and is slightly inhibitory. 
 It is likely that HIV-1 has evolved to incorporate UDM proteins into virus 
particles for some purpose which is beneficial for viral replication and dissemination. 
Currently, however, this purpose remains unknown. Alternatively, it is possible that Gag-
UDM interactions are simply a consequences of the unique way in which Gag binds to 
and recognizes membranes. It may also be possible that Gag interaction with class I 
UDMs is necessary for polarization of Gag in T cells. While replacement of the MA 
domain with a triple-acylation signal derived from Fyn kinase results in association of 
Gag with a different set of UDMs, it does not inhibit polarization of Gag [20]. This result 
was initially interpreted as indicating that association between Gag and class I UDMs is 
dispensable for Gag polarization to uropods.  
However, an alternative model is also possible. We have previously found that 
constructs containing this Fyn modification are severely deficient in infection of T cells 
(GNL, JRG unpublished observations). This may indicate that the inability of MA to 
detach from the membrane may have detrimental effects during viral entry, uncoating, or 
nuclear import. Therefore, it is possible that although association of Gag bearing the Fyn 
membrane binding sequence with different UDMs can support polarization of Gag to 
uropods in T cells, association of Gag with class I UDMs is required for polarization of 
Gag bearing a WT Matrix sequence. It is also formally possible that association of 
Fyn(10)-Gag with a different subset of UDMs is detrimental to viral infectivity. 
We favor the possibility that UDM proteins may serve some purpose during viral 
infection. We are currently developing a trans-infection model, which will be described 
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in chapter 4 of this thesis. Using this assay, we aim to determine whether UDM proteins 
modulate trans-infection of T cells by virus particles which have been previously 
captured by dendritic cells. Development of additional models will likely be necessary to 
understand the role UDM proteins play in HIV infection in vivo. It is possible that 
simplified cell-based assays do not adequately reflect the complexity of HIV biology 
which occurs within the human body, especially within the complicated cellular milieu of  
secondary lymphoid tissues. 
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Summary of Results 
 Interactions between assembling HIV-1 virions and plasma membrane proteins 
present in host cells likely constitute an important mechanism of selective incorporation 
of beneficial cellular components into virus particles. Furthermore, exclusion of certain 
proteins by HIV-1 is also likely to enhance viral replication and dissemination in vivo. In 
chapter 2 of this thesis I have defined the mechanism by which an antiviral protein, BST-
2/tetherin is incorporated into HIV-1 assembly sites in the absence of viral antagonism. In 
chapter 3 of this thesis, I have addressed the mechanism by which HIV-1 selectively 
incorporates certain uropod-directed microdomain (UDM) proteins into virus assembly 
sites. 
 While many have speculated that tetherin is incorporated into HIV-1 virus 
assembly sites through a lipid raft-dependent mechanism, I have shown evidence that this 
is not the case (Figure 2.2). I have also shown that tetherin does not appear to associate 
with lipid raft markers that can be found in association with HIV-1 assembly sites (Figure 
2.1) [1]. This model of lipid-raft dependent recruitment of tetherin was based on the 
observations that cholesterol-depletion drastically decreases HIV-1 virus particle 
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production [2], and that tetherin can be recovered from detergent-resistant membrane 
fractions [3]. 
 Findings presented in chapter 2 of this thesis are consistent with the observation 
of another group, that tetherin does not associate with GM-1, a lipid raft marker [4]. They 
are also consistent with the finding that association of Vpu with detergent-resistant 
membrane fractions is not correlated with its ability to antagonize tetherin [5]. 
Furthermore, another group has shown that antagonism of tetherin function by Vpu does 
not involve removal of tetherin from detergent-resistant membrane fractions [6]. 
Together these results support a model where tetherin localization to HIV-1 assembly 
sites is a lipid raft-independent process, and that lipid raft association of tetherin and Vpu 
is dispensable for the association and function of these proteins. 
 Through the use of confocal and super-resolution localization microscopy 
techniques, I was able to demonstrate that both membrane curvature, specifically 
determined by residues in the N-terminal region of the capsid (CA) domain of Gag, as 
well as interactions between Gag and components of the endosomal sorting complex 
required for transport (ESCRT) mediate and enhance tetherin recruitment to HIV-1 
assembly sites respectively (Figures 2.3, 2.5 and 2.7). I was also able to demonstrate that 
Gag-ESCRT interactions enhance tetherin recruitment in a T cell line, as late domain 
mutations significantly reduced tetherin-Gag colocalization in these cells (Figure 2.4). 
 Finally, I found that while disruption of Gag-ESCRT interactions significantly 
reduces tetherin recruitment, to levels undetectable by confocal microscopy (Figures 2.3 
and 2.5), tetherin is still recruited at low levels under these conditions (Figure 2.7). I also 
found that these low levels of tetherin recruitment are sufficient for full restriction of 
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HIV-1 virus particle release in HeLa and T cells (Figure 2.6). 
 Previous studies in our laboratory have shown that Gag co-polarizes to uropods 
along with a subset of uropod directed microdomain proteins. We have also shown that 
polarization of both Gag and UDMs is dependent on an intact actin myosin system. 
Additionally, we have demonstrated that polarization of Gag is dependent upon Gag 
multimerization, specifically that mediated by the NC domain [7]. Recently, we have 
identified the MA HBR as the critical determinant which mediates Gag-UDM 
interactions [8]. 
 In ongoing studies, which are presented in chapter 3 of this thesis, I address the 
mechanism by which HIV-1 is able to associate with certain uropod-directed proteins 
present in T cells. While previous studies have characterized which proteins are brought 
to HIV-1 assembly sites, and which appear to be excluded by Gag, they have not 
addressed either the underlying mechanism of Gag-UDM association or the relevance of 
these interactions to HIV-1 biology [7, 8]. 
 To extend on these previous studies in T cells, which were carried out using an 
antibody co-patching assay, I have employed super-resolution microscopy techniques 
developed in chapter 2 of this thesis to determine the nature of Gag-UDM interactions in 
greater detail. I first tested whether Gag-UDM association occurs in HeLa cells, which 
are more tractable to TIRF microscopy, transgene introduction, and siRNA-mediated 
protein depletion. Consistent with previous findings, I observed high levels of co-
clustering between Gag and PSGL-1 when both were expressed exogenously (Figure 
3.1). This result indicates that HeLa cells constitute an acceptable model in which to 
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study Gag-UDM interactions, because the necessary determinants of these interactions 
are also present in these cells. 
 Using PSGL-1 as a model UDM protein, I next sought to identify the 
determinants of Gag-PSGL-1 interaction. I found that consistent with our findings in T 
cells, the MA HBR is required for efficient recruitment of PSGL-1 to virus assembly sites 
(Figure 3.1). In contrast to previous observations, however, I found that exchanging the 
identity of basic residues in the HBR did not completely restore PSGL-1 recruitment. 
While this observation may reflect cell-type-specific differences between HeLa and T 
cells, the use of different methods may also contribute to the quantitative differences 
observed between the current and previous studies. Of note, it is likely that super-
resolution localization microscopy more accurately captures the native distribution of 
proteins, as it does not require antibody copatching prior to fixation.  
I next sought to identify the determinants present in PSGL-1 which mediate its 
recruitment to virus assembly sites. I found that deletion of the cytoplasmic tail of PSGL-
1 resulted in a drastic reduction in PSGL-1 recruitment, while mutation of a cysteine 
residue critical for dimerization of PSGL-1 had no effect (Figure 3.2). Given that the 
cytoplasmic tail of PSGL-1 contains the major determinants of its recruitment to HIV-1 
assembly sites, I examined the sequence of the cytoplasmic tail of this protein and formed 
two hypotheses. First, that acidic residues within the cytoplasmic tail of PSGL-1 may 
interact directly with the MA HBR. Second, that basic residues near the transmembrane 
domain of PSGL-1 may mediate its recruitment to assembly sites presumably through 
interaction with some acidic, intermediate factor.  
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By making mutations in these two regions of PSGL-1, and observing these 
proteins by super-resolution microscopy, I found that three membrane-proximal basic 
residues constitute the major determinant of PSGL-1 recruitment to virus assembly sites 
(Figure 3.3). While mutation of acidic residues near the C-terminus of the protein 
appeared to increase surface levels of PSGL-1, it did not affect co-clustering with Gag 
(Figure 3.3). 
It is well known that two of the residues substituted in the basic residue mutant, 
PSGL-1 3A, constitute an Ezrin binding site in PSGL-1 [9]. This interaction is thought to 
be required for polarization of this protein to T cell uropods. It is possible that this 
interaction may also mediate association of PSGL-1 with HIV-1 assembly sites. 
Unexpectedly, I found that depletion of Ezrin, Radixin, and Moesin individually had no 
significant effect on Gag-PSGL-1 co-clustering. However, I found that depletion of all 
three proteins simultaneously resulted in increased co-clustering (Figure 3.4). This result 
indicates that rather than being necessary for Gag-PSGL-1 interaction, these proteins are 
slightly inhibitory to this interaction, in a redundant manner. 
Taken together, the results presented in chapter 3 of this thesis (Figures 3.1 – 3.4) 
indicate that basic residues are necessary on both sides of the interaction between Gag 
and PSGL-1. Given these findings, I hypothesized the existence of some acidic factor 
which mediates recruitment of PSGL-1, as well as other UDM proteins to HIV-1 
assembly sites. Given the proximity to the membrane, this factor is likely an acidic lipid, 
of which many different types can be found in the inner leaflet of the plasma membrane. 
Future experiments, using chimeric Gag constructs with different lipid specificities, 
should be able to determine the identity of this unknown factor, if it is indeed an acidic 
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lipid. Alternatively, it is also possible that this factor could be a protein, small molecule, 
or nucleic acid, which is membrane-proximal and links Gag and PSGL-1. 
Finally, I sought to determine the functional significance of recruitment of UDM 
proteins to virus assembly sites in the context of HIV-1 replication and spread. To 
address this, I tested the effects of expression of class I and II UDM proteins in 293T 
cells also expressing a full-length molecular clone of HIV (pNL4-3). By this method, I 
observed a modest inhibition of viral infectivity by all proteins tested, with the exception 
of ICAM-1 (Figure 3.5). However, this protein was also somewhat inhibitory when 
bearing the cytoplasmic tail of PSGL-1 (Figure 3.5). This finding likely reflects the 
absence of wild type ICAM-1 in association with viral assembly sites [8]. 
Next, I tested the effect of expression of UDM proteins on cell-to-cell transfer. 
This was done by expressing a molecular clone which encodes Gag-YFP, along with 
plasmids encoding UDM proteins, in HeLa cells. These cells were then washed and co-
cultured with SupT1 T cells. After a 3 hour co-incubation, cells were fixed and analyzed 
by FACS to quantify the relative amounts of VLPs which had been transferred to target T 
cells. We have previously shown robust acquisition of Gag-YFP virus-like particles 
(VLPs) by T cells using a similar assay [7]. Consistent with the results of the infectivity 
experiment, I found that expression of UDM proteins modestly inhibited cell-to-cell 
transfer of Gag-YFP VLPs (Figure 3.5). Further experiments will be necessary to directly 
assess to what extent these proteins are incorporated into virus particles under these 
conditions. Development of additional assays will also likely be needed to clarify the role 





 In chapter two of this study, I have presented data consistent with a model in 
which membrane curvature, induced by HIV-1 virus assembly, mediates recruitment of 
tetherin to virus assembly sites. This observation has many potential implications. 
Structural studies of tetherin have shown that it possesses some structural similarities 
with other proteins which can sense and manipulate membrane curvature [10].  
Structural analyses have also revealed the presence of positively-charged residues 
near the ends of the ectodomain of tetherin, which may allow it to interact with the 
negatively-charged extracellular face of the plasma membrane, while negatively-charged 
residues in the central portion may repel the membrane [10, 11]. In addition to this 
observation, tetherin has been found to display considerable flexibility, determined by the 
presence of two possible hinge regions in this protein [10, 11]. It has been suggested that 
while tetherin is primarily a dimeric protein, it possess the ability to form tetrameric 
complexes under reducing conditions [10, 12], however mutation of a residue critical for 
this tetramerization (L70D) only modestly decreased the potency of virus release 
inhibition by tetherin [12]. Therefore, while tetramerization of tetherin may enhance its 
capacity to sense membrane curvature, it is not required for inhibition of HIV-1 release. 
While results presented in chapter 2 of this thesis are consistent with a model 
where tetherin is able to sense membrane curvature induced by viral assembly, it would 
be interesting to determine whether residues which confer flexibility to the ectodomain of 
tetherin (A88 and G109) are required for this curvature-sensing ability [11]. 
I have also shown that ESCRT proteins, specifically Tsg101 and Alix, both 
enhance tetherin recruitment to virus assembly sites; however this enhancement is not 
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necessary for inhibition of HIV-1 release. Currently, it is not known whether these 
proteins directly recruit tetherin to HIV-1 assembly sites, or if downstream ESCRT 
components are required for this activity. It is also unclear how ESCRT engagement 
enhances tetherin recruitment. If the latter possibility is correct, that Tsg and Alix 
enhance tetherin recruitment through downstream ESCRT components such as ESCRT-
III [13], it is possible that polymerization of ESCRT-III proteins may form a barrier 
which prevents diffusion of tetherin away from assembly sites . 
Another possibility is that ESCRT-induced membrane deformation, which 
ultimately progresses to membrane scission, may create a unique environment in which 
extreme membrane curvature is present [13-15]. Though difficult to address 
experimentally, if this hypothesis were correct, it would further strengthen the model in 
which tetherin is inherently a sensor of membrane curvature. 
Furthermore, while ESCRT-dependent enhancement of tetherin recruitment is not 
necessary for restriction of HIV-1 release, it is possible that other larger enveloped 
viruses, which like HIV-1 rely on ESCRT machinery for fission, may be susceptible to 
these higher levels of tetherin recruitment. It is likely that as larger viruses like filoviruses 
and filamentous orthomyxoviruses may experience greater shearing forces, they may also 
require more tetherin molecules to retain them at the cell surface.  
Additionally, it is currently not known whether tetherin inhibits budding of other 
particles from the cell surface, such as exosomes or other vesicles. If tetherin recruitment 
is indeed dependent upon membrane curvature, these other budding events may also be 
sensitive to tetherin. It would be interesting to examine whether other ESCRT-dependent 
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membrane budding events, such as MVB formation, cytokinesis, and autophagy are also 
inhibited by tetherin [14]. 
Recently, it has been reported that tetherin may serve as an innate sensor for viral 
infection. This hypothesis is supported by the observation that tetherin expression 
enhances NF-B activity in a virus-dependent manner [16, 17]. Furthermore, another 
study found that while expression of an MLV clone resulted in tetherin-dependent 
induction of NF-B, mutation of the late domain of MLV Gag abolished this induction 
[18]. If tetherin is indeed a true pathogen recognition receptor, it would be interesting to 
determine whether ESCRT-mediated enhancement of tetherin recruitment to HIV-1 
assembly sites also enhances NF-B activation upon HIV-1 infection. While membrane 
curvature can induce sufficient recruitment of tetherin to inhibit virus release, it is 
possible that additional recruitment may be necessary to initiate or strengthen NF-B 
signaling by tetherin in response to HIV-1 infection. 
 In chapter 3 of this thesis, I have presented data which are consistent with a model 
where UDM proteins are recruited to HIV-1 assembly sites through the presence of an 
acidic intermediate. It is currently unknown whether this intermediate factor is a lipid, 
protein, or nucleic acid. Experiments are currently underway to separate these 
possibilities. As these studies have only examined the mechanism of PSGL-1 
recruitment, it will be interesting to determine whether CD43 and CD44 are recruited to 
HIV-1 assembly sites through a similar mechanism. Also, the mechanism by which Gag 
is able to exclude other UDM proteins, such as ICAM-1 and ICAM-3, from virus 
assembly sites remains unknown. 
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 It would also be interesting to determine at which stage of viral assembly UDM 
interactions take place. This could be done by examining both early assembly mutants I 
developed in collaboration with Nick Llewellyn in our laboratory [8], and late stage 
mutants described in chapter 2 of this thesis and elsewhere [8, 19] by super-resolution 
microscopy. Interestingly, we found that while a Gag molecule bearing a trimeric leucine 
zipper sequence did not polarize to uropods in T cells, a similar construct bearing a 
tetrameric leucine zipper sequence polarized to a similar extent to wild type Gag [8].
 Furthermore, the functional consequences of HIV-UDM interactions remain to be 
fully elucidated. Thus far, I have examined the effects of these proteins on infectivity and 
cell-to-cell transfer of HIV-1. Unexpectedly, all UDM proteins tested modestly decrease 
both infectivity and virus transfer, with the exception of ICAM-1. Development of 
additional assays will be necessary to examine what role, if any, UDM proteins play in 
HIV-1 replication and dissemination, and whether these proteins indeed confer some 
advantage to HIV-1 as I have hypothesized. 
 Currently, I am working to develop a trans-infection assay using a human 
monocytic cell line, THP-1. Through the addition of cytokines, these cells can be induced 
to differentiate into cells exhibiting characteristics of both immature and mature dendritic 
cells (iDC and mDC) [20]. Given that the class II UDM protein ICAM-3 is a natural 
ligand for DC-SIGN, which mediates trans-infection of T cells by dendritic cell-
associated HIV-1 [21-23], I hypothesized that this protein may interfere with the process 
of trans-infection if incorporated into HIV-1 virions. Thus far, I have successfully derived 
cells with iDC and mDC characteristics, including DC-SIGN expression, adherence, and 
cell morphology (Figure 4.1 A-B). I have also observed robust trans-infection of CEM-
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GFP cells when THP-1-derived iDC and mDC were pre-incubated with virus. In this 
assay, CEM-GFP cells were observed making extensive contacts with iDC and mDC, and 
appear to exhibit contact-induced polarization, although this has not yet been assessed 
quantitatively (Figure 4.1 C). I am currently in the process of determining whether UDM 
proteins modulate trans-infection in this system. 
 
 
Figure 4.1. Development of a trans-infection assay using THP-1-derived, human dendritic cells. 
A) THP-1 cells (a human monocytic cell line) were incubated in RPMI containing 10% FBS, or media 
containing 10% FBS, rhGM-CSF, and rhIL-4 for 5 days (iDC), or media lacking FBS containing rhGM-
CSF, rhIL-4, rhTNF-, and ionomycin for 3 days (mDC). While THP-1 cells are primarily round and not 
adherent, iDC display a lobate morphology and are weakly adherent, while mDC display a stellate 
morphology and are strongly adherent, similar to iDC and mDC derived from primary human monocytes. 
B) Cells were then fixed and analyzed for surface DC-SIGN expression by FACS analysis. C) Cells 
cultured under the conditions described above were inoculated with single-round HIV-1 virus particles 
(pNL4-3 Env- + pEBB NL-Env) obtained from 293T cells. After 2 hour incubation, cells were washed and 




 In chapters 2 and 3 of this thesis, I have developed quantitative super-resolution 
localization microscopy techniques well suited to the study of virus-host interactions.  
These techniques are able to resolve single virus particles as well as single host proteins, 
and are likely not prone to significant antibody-mediated artifacts. Prior to  
immunostaining, cells are fixed with paraformaldehyde and glutaraldehyde to prevent 
diffusion of transmembrane proteins observed in these experiments [24]. Although these  
techniques are quantitative and able to resolve proteins distributions with extremely high 
precision (10-30 nm), they have been limited to two colors in the experiments presented 
in this thesis. 
 It is formally possible that 3 color imaging could be performed under similar 
conditions. In particular, YFP is able to fluoresce strongly under reducing conditions, and 
is spectrally distinct from both Alexa Fluor 532 and Alexa Fluor 647. In a pilot 
experiment, I was able to observe YFP by TIRF, along with Alexa Fluors 532 and 647 by 
dSTORM (Figure 4.2). While super-resolution information was not extrapolated from 
YFP signals, it could also be possible to use Alexa Fluor 488 with Alexa 647 and either 
Alexa Fluor 532 or mEos3.2. YFP has also been used successfully for PALM imaging 
previously [25], although it may not be compatible with reducing buffers commonly used 
for dSTORM. Another combination of Alexa Fluors 488, 561, and 647 has been reported 
previously [26]. I am currently in the process of exploring these possibilities to further 






Figure 4.2. Demonstrating the feasibility of triple-color super-resolution localization microscopy. 
HeLa cells were transfected with plasmids encoding Gag-YFP, ICAM-3, and PSGL-1. Cells were fixed and 
stained with an Alexa Fluor 532-labeled antibody against ICAM-3, and an Alexa Fluor 647-labeled 
antibody against PSGL-1. Cells were first imaged by TIRF to obtain YFP images, followed by dSTORM 
imaging to determine the location of molecules of ICAM-3 and PSGL-1 with high precision (~15 nm). YFP 
is shown in gray, ICAM-3 is shown in green, PSGL-1 is shown in red. Notably, PSGL-1 is seen in 





 HIV-1 is an extremely successful viral pathogen. Although infection progresses 
slowly, especially when HAART therapy is employed, it is nearly always fatal due to the 
emergence of drug-resistant viruses. There is only one known case where an HIV-1 
positive individual has been cured completely of infection, by bone marrow 
transplantation from a CCR5 32 homozygous donor [27]. While pathogen elimination is 
always the goal of therapeutic intervention, this has proved difficult in the case of HIV. 
This is primarily due to three factors. First, as a retrovirus, HIV-1 becomes integrated 
into the chromosomal DNA of host cells [28]. Second, HIV-1 is able to establish 
extremely long lived latent reservoirs [29]. Third, HIV-1 is able to inhibit many immune 
mechanisms that would otherwise result in its elimination from the body [30-32]. 
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 Once infection has been established, HIV-1 is extremely efficient at avoiding or 
circumventing host immune responses. Many viruses, including HIV-1, frequently escape 
control by the adaptive immune system through mutation of immunogenic epitopes of 
viral proteins. As discussed in chapter 1 of this thesis, immune evasion can also be 
accomplished through the activities of the HIV-1 accessory proteins Vif, Vpr, Vpu, and 
Nef. In some cases, immune evasion can also result from mutation of the viral targets of 
cellular restriction factors. While most HAART drugs have been developed to target the 
viral enzymes, the viral envelope, and viral receptors [33] it may also be possible to 
target the activities of accessory proteins as well. It is likely that the extremely high levels 
of selective pressure exerted on HIV-1 by these conventional therapies frequently results 
in the emergence of drug resistance. As the accessory proteins of HIV-1 have been shown 
to be dispensable for viral replication in cell culture, they are thought to enhance 
virulence and pathogenicity in vivo primarily through the antagonism of various immune 
pathways. 
 It is conceivable that targeting viral accessory proteins through pharmacologic 
intervention may significantly reduce pathogenesis of HIV-1, while still allowing viral 
replication to occur. This may relieve some of the selective pressure imposed by 
conventional HAART therapy and result in less frequent development of drug resistance, 
which is an ongoing problem in the application of HAART therapy. Alternatively, 
regimens could be developed which target both viral enzymes and accessory proteins. In 
order to be able to develop inhibitors of the accessory proteins, we must first understand 
their functions in greater detail. As most accessory proteins target antiviral restriction 
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factors, also discussed in chapter 1 of this thesis, we must also work to understand the 
functions of restriction factors.  
Another strategy which may prove useful would be to devise ways to enhance the 
functions of restriction factors. Toward this end, I have examined and defined the 
mechanism by which tetherin is recruited to HIV-1 assembly sites in chapter 2 of this 
thesis. Along with many other studies into the function of this protein, this information 
may prove useful in the development of strategies to inhibit Vpu function, or alternatively 
enhance tetherin antiviral function. 
 Other approaches are likely to prove useful in combating HIV-1 infection and 
disease progression. These include identification and characterization of latent viral 
reservoirs. Once well understood, it may be possible to either eliminate these reservoirs, 
or induce their reactivation which may promote clearance of infected reservoirs by the 
immune system [34-36]. 
 Gene therapy is another promising tool for the eradication of HIV-1. While 
current studies are focused on replacement of wild type CCR5 genes with the 32 allele 
[37], it may also be possible to introduce genes encoding more potent versions of known 
restriction factors by gene therapy techniques. For example, the TRIM5 protein found 
in Rhesus macaques potently inhibits HIV-1, unlike the human homologue of this protein 
[38]. Alternatively, introduction of a tetherin variant which is insensitive to Vpu 
antagonism may also be useful [39]. 
 While the conventional view of viral replication is that viruses simply utilize 
cellular components to promote their replication, recent findings point to viruses like HIV 
hijacking or repurposing cellular pathways to their advantage. In many cases, this is 
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manifest as the creation of a specific cellular niche in which viruses replicate. For 
example, many enveloped viruses utilize the ESCRT machinery to accomplish scission of 
host and viral membranes. This involves redirection of a complex normally associated 
with intracellular membranes to the plasma membrane of the cell [40].  
 Work from our laboratory, as well as many others, has shown that HIV-1, 
primarily through the Gag protein, specifically reorganizes both lipid and protein 
components of the host cell plasma membrane [19]. In particular, it selectively associates 
with certain domains in T cells [7, 8]. As discussed in chapter 3 of this thesis, HIV has 
likely evolved to interact specifically with these proteins for some purpose. Although this 
purpose is not yet clear, it may be related to cell-to-cell transfer of virus from infected to 
uninfected cells. 
 We have observed that HIV-1 preferentially associates with PSGL-1, CD43, and 
CD44 [7, 8]. CD43 and PSGL-1 bind specifically to a class of adhesive proteins present 
on endothelial cells termed selectins. This interaction promotes leukocyte rolling along 
endothelial surfaces [41]. In the context of HIV-1, it is possible that these proteins are 
specifically incorporated into virus particles to facilitate their attachment to endothelial 
surfaces. By doing this, HIV-1 may be more efficiently acquired by rolling leukocytes in 
the vasculature and lymphatic systems. CD44 is a receptor for extracellular matrix 
components, particularly hyaluronic acid, and is involved in migration, homing, and 
activation of T cells [42]. It is possible that HIV-1 incorporates this protein to allow it to 
attach to the extracellular matrix (ECM) of uninfected cells prior to viral entry. 
Alternatively, retention of progeny virions at the surface of infected cells by CD44-ECM 
interactions may potentially enhance cell-to-cell transfer of virus. 
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 We have observed that two other UDM proteins, ICAM-1 and ICAM-3, are 
actively excluded from HIV-1 assembly sites [7, 8]. Both of these proteins bind to 
integrins such as LFA-1 (-L/-2). LFA-1 is primarily localized at the leading edge of 
polarized T cells [7]. It is possible that incorporation of ICAM-1 and ICAM-3 into virus 
particles would increase their adhesion to LFA-1 on the surface of producer T cells. As 
LFA-1 polarizes away from the uropod in infected cells, where virolgical synapses (VSs) 
form and cell-to-cell transmission likely occurs [7], HIV-1 may have evolved to avoid 
incorporation of these proteins in order to prevent its relocation away from sites of cell-
cell contact. 
 Interestingly, we have recently reported that ICAM-3 is present in association 
with CD44 in uninfected T cells. However, when HIV-1 Gag is expressed, this protein is 
actively excluded from Gag-associated UDMs [8]. It is tempting to speculate that this 
specific exclusion of ICAM-3 from virus assembly sites must serve some function in 
viral replication. In addition to LFA-1, ICAM-3 is also known to bind to DC-SIGN, a 
lectin present on dendritic cells, which facilitates HIV-1 trans-infection [21]. It is possible 
that acquisition of virus by dendritic cells, while able to enhance trans-infection of T 
cells, may also result in increased presentation of virus-derived antigens to the adaptive 
immune system. Therefore, if ICAM-3 were efficiently incorporated into virus particles it 
may be detrimental to viral immune evasion strategies. Consistent with this hypothesis, 
enhanced replication of HIV-1 has been observed in cells lacking ICAM-3 [43].  
HIV-1 lacks the Vpx accessory protein, found in related viruses SIV and HIV-2. 
As this protein is known to enhance infection of macrophages and dendritic cells by 
antagonism of SAMHD1 [44], it may be that HIV-1 has evolved to be primarily a 
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pathogen of T cells, and therefore lacks this accessory protein. In the case of HIV-1, 
evolution may have favored robust infection of T cells rather than infection of 
macrophages and dendritic cells, which possess many antiviral properties and the ability 
to efficiently present viral antigens. This may, in turn, explain the less severe pathology 
associated with HIV-2 and SIV infection in their natural primate hosts compared to that 
observed with HIV-1 in humans. Regardless of the specific roles played by these proteins 
in HIV-1 replication, many further studies will be necessary to fully understand how 
HIV-1 has become such a successful pathogen in humans, how it manipulates immune 
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